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Abstract 
The  first  line  medication  for  mild  to  moderate  Alzheimer’s  disease  (AD)  is  based  on  
cholinesterase inhibitors which prolong the effect of the neurotransmitter acetylcholine in 
cholinergic nerve synapses which relieves the symptoms of the disease. Implications of 
cholinesterases involvement in disease modifying processes, has increased interest in this 
research area. 
 
The drug discovery and development process is a long and expensive process that takes on 
average 13.5 years and costs approximately 0.9 billion US dollars. Drug attritions in the 
clinical phases are common due to several reasons, e.g., poor bioavailability of compounds 
leading to low efficacy or toxic effects. Thus, improvements in the early drug discovery 
process are needed to create highly potent non-toxic compounds with predicted drug-like 
properties. 
 
Nature has been a good source for the discovery of new medicines accounting for around 
half of the new drugs approved to market during the last three decades. These compounds 
are direct isolates from the nature, their synthetic derivatives or natural mimics. Synthetic 
chemistry is an alternative way to produce compounds for drug discovery purposes. Both 
sources have pros and cons. The screening of new bioactive compounds in vitro is based 
on assaying compound libraries against targets. Assay set-up has to be adapted and 
validated for each screen to produce high quality data. Depending on the size of the 
library, miniaturization and automation are often requirements to reduce solvent and 
compound amounts and fasten the process. 
 
In this contribution, natural extract, natural pure compound and synthetic compound 
libraries were assessed as sources for new bioactive compounds. The libraries were 
screened primarily for acetylcholinesterase inhibitory effect and secondarily for 
butyrylcholinesterase inhibitory effect. To be able to screen the libraries, two assays were 
evaluated as screening tools and adapted to be compatible with special features of each 
library. The assays were validated to create high quality data. 
 
Cholinesterase inhibitors with various potencies and selectivity were found in natural 
product and synthetic compound libraries which indicates that the two sources 
complement each other. It is acknowledged that natural compounds differ structurally 
from compounds in synthetic compound libraries which further support the view of 
complementation especially if a high diversity of structures is the criterion for selection of 
compounds in a library.  
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Abbreviations 
1D, 2D, 3D one-dimensional, two-dimensional, three-dimensional 
?? amyloid-? peptide 
AChE acetylcholinesterase 
ACN acetonitrile 
AD Alzheimer’s disease 
ADME absorption, distribution, metabolism, excretion 
APP amyloid precursor protein 
aq aqueous 
ATCI acetylthiocholineiodide 
BBB blood-brain barrier 
BChE butyrylcholinesterase 
ca. circa 
CHCl3 chloroform 
CNS central nervous system 
CV coefficient of variance 
DAD diode array detector 
DMSO dimethylsulphoxide 
DTNB dithionitrobenzoic acid, Ellman’s reagent 
ESI electrospray ionization 
e.g. exempli gratia, for example 
FDA Food and Drug Administration in U.S.A. 
HPLC high performance liquid chromatography 
HRMS high-resolution mass spectrometry 
HTS high-throughput screening  
IC50 concentration yielding 50% inhibition 
i.e. id est, that is  
Ki dissociation constant for an inhibitor for binding to the enzyme 
LC liquid chromatography 
MeOH methanol 
MCI mild cognitive impairment 
MS mass spectroscopy, mass spectrometry 
NMDA N-methyl-D-aspartic acid 
NMR nuclear magnetic resonance spectroscopy 
qNMR quantitative nuclear magnetic resonance spectroscopy 
PAS peripheral anionic site 
PC principal component 
QSAR quantitative structure-activity relationship 
Rf retardation factor or retention factor 
RP reversed-phase 
SAR structure-activity relationship 
SDb standard deviation of the background 
SDs standard deviation of the signal 
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S/B signal-to-background 
S/N signal-to-noise 
TFA trifluoroacetic acid 
TLC thin-layer chromatography 
UV ultra violet 
Vis visible 
Xb average of the background 
Xs average of the signal 
Z’ screening window coefficient 
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1 Introduction 
Drug discovery and development is a long and expensive process that takes ca. 13.5 years 
on average and costs approximately 0.9 billion US dollars per new molecular entity launch 
(Paul et al. 2010). Clinical trials (I-IV) are the most expensive phases in the whole process 
accounting  for  around  63%  of  the  total  costs.  Withdrawals  in  these  phases  are  still  
common since nine molecules are needed to enter the clinical phase I to yield one new 
molecular entity launch. More attention should be paid to the quality of research in the 
proceeding stages to create better lead molecules for clinical trials that are effective, non-
toxic and drug-like and whose bioavailability is good. The improvement of the quality of 
data created and combination of in vitro and in silico approaches are means to make the 
process more efficient. 
 
Several molecular sources for in vitro drug discovery are available from which natural 
products and synthetic compound libraries are the main ones. Nature has been a good 
source  for  new  medicines  accounting  for  nearly  half  of  all  the  new  chemical  entities  
launched on market during 1981-2006 (Newman et al. 2003, Newman and Cragg 2007). 
These compounds are direct isolates from the nature, semi-synthetic or synthetic 
derivatives of natural molecules, proteins or natural mimics. In spite of this knowledge, 
there is reduced interest in natural product research among pharmaceutical companies 
because natural compounds tend to be problematic in lead optimization phase from 
medicinal chemistry perspective due to asymmetric carbon atoms and poor ADME 
properties (ADME, absorption, distribution, metabolism, excretion). With help of 
combinatorial chemistry it is possible to make large synthetic compound libraries of 
hundreds of thousands of compounds. Low volume assays and automatic liquid handling 
robotics allow screening for bioactive compounds from the large pure compound libraries. 
The realization that increases in throughput have not increased the number of approvals of 
synthetic entities has been a huge disappointment for the pharmaceutical industry (Li and 
Vederas 2009). 
 
Natural product scaffolds are more complex in structure than synthetic drugs or 
compounds in synthetic compound libraries (Lee and Schneider 2001, Feher and Schmidt 
2003, Ortholand and Ganesan 2004, Newman 2008, Rosen et al. 2009, Sukuru et al. 
2009). This has been postulated to be the reason why synthetic compounds have failed to 
supplant natural products. The handling of extracts as well as the isolation and 
identification of active compounds from extracts have traditionally been pitfalls in natural 
product research (Hamburger 2003, Potterat and Hamburger 2006). Recent improvement 
in analytical technologies, especially chromatographic and spectroscopic methods, have 
shortened the times of analyses and decreased the amount of compounds needed for 
identification of molecular structures (Eldridge et al. 2002, Dalisay and Molinski 2010). 
This development will draw attention back to natural products. Natural product pure 
compound libraries and well designed pre-fractionated extract libraries are compatible 
with  HTS  platforms,  and  therefore  are  available  for  large  scale  screening  (Sukuru  et  al.  
2009, Wagenaar 2008). In addition, coupling of analytical methods to bioactivity assays is 
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a means to facilitate the drug discovery of natural products because simultaneously created 
information on bioactivity and structural data eases the identification of bioactive 
compounds (Potterat and Hamburger 2006). 
 
Approximately 13,000 new dementia cases are diagnosed every year in Finland 
(Suhonen et al. 2010). It was estimated in 2005 that 24 million people worldwide suffered 
from dementia and the amount of incidents doubles every 20 years because of the trend in 
the aging of the population which makes dementia a huge burden for health care systems 
(Ferri et al. 2005). Alzheimer’s disease is the most common form of dementia. 
Alzheimer’s disease is a neurodegenerative disorder that slowly and steadily deteriorates 
memory and other cognitive functions (McKhann et al. 1984, Dubois et al. 2007). There is 
no cure for the disease or means to stop its progression. The first line medication is based 
on cholinesterase inhibitors which are compounds that prolong the effect of 
neurotransmitter acetylcholine in cholinergic synapses by inhibiting the degrading enzyme 
acetylcholinesterase (Birks 2006). The medication relieves the symptoms of the disease. 
Indications that cholinesterase inhibitors could also modify the disease have increased 
research efforts on this target. 
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2 Review of the Literature 
2.1 Dementia 
Dementia has been defined as the deterioration of more than one of the cognitive functions 
to the extent that it impairs a person’s ability to perform daily functions independently 
(McKhann et al. 1984, Sulkava 2010). In dementia, the cognitive impairment is due to an 
organic cause. People with mild cognitive impairment (MCI) have memory impairments 
but do not meet the clinical criteria for dementia. MCI is often considered a transition 
stage between normal aging and dementia (Dubois et al. 2007, Petersen et al. 1999). 
 
Age and genetic susceptibility are the only well established risk factor for dementia 
(Qiu et al. 2007). Incidences of dementia increase exponentially with age (Fratiglioni et al. 
2000, Berr et al. 2005). Consequently, the trend in the aging of population will increase 
the number of dementia incidents. The number of incidents is estimated to be near 50 
million worldwide in the year 2025 (Ferri et al. 2005). There is no cure for dementia so far 
which makes it a huge burden for health care systems worldwide. Costs of care increase 
with the progression of dementia (Jönsson and Berr 2005, Jönsson and Wimo 2009). 
Etiological studies have implicated that control of risk factors for vascular disorders 
including hypertension, type 2 diabetes, hyperlipidaemia and smoking decrease the risk of 
dementia and may delay the onset of disease (Ferri et al. 2005, Qiu et al. 2007). 
 
Alzheimer’s disease (AD) is the most common form of dementia in people older than 
the age of 65. AD represents 60 to 70% of demented cases whereas the  second  most  
common dementia, vascular dementia, accounts for about 15 to 20% of the cases 
(Fratiglioni et al. 2000). Other forms of dementia are e.g. Lewy body dementia, 
Parkinson's disease with dementia, Frontotemporal dementia, Huntington's disease and 
Creutzfeldt-Jakob disease. This literature review focuses further on AD. 
2.2 Alzheimer’s Disease 
AD is a progressive neurodegenerative disease that slowly and steadily deteriorates 
memory and other cognitive functions (McKhann et al. 1984, Dubois et al. 2007). Other 
symptoms are alteration of mood and delusions but also hallucinations are possible. 
Symptoms of AD usually begin with difficulties in the acquisition of new skills and 
finding words because of memory disturbances. Duration of the disease from first 
symptoms to death is approximately 12 years (range 2–20 years) (Sulkava 2010). Men 
diagnosed  with  AD  die  earlier  after  the  onset  of  the  disease  than  females  with  AD  
(Williams et al. 2006). 
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Hallmark findings in postmortem AD brains are extracellular amyloid plaques and 
intracellular neurofibrillary tangles (McKhann et al. 1984, Glenner and Wong 1984, Braak 
et al. 1996, Schliebs and Arendt 2006, Kern and Behl 2009). The spatial and temporal 
connections between these two pathological hallmarks are not completely understood and 
are, thus, under constant debate. In addition, cholinergic neuronal depletion is established 
in AD which influences the cognitive deficits (Mesulam 2004). AD proceeds in stages. 
Destructive process begins in areas of the cerebral cortex and specific sub-cortical nuclei 
in a consistent and predictable sequence (Braak et al. 1999). Eventually AD damages the 
primary motor area and primary sensory fields. 
 
The correlation is strong between accumulation of amyloid plaques and neurofibrillary 
tangles in the hippocampal region and memory decline over time (Näslund et al. 2000, 
Reitz et al. 2009). The pathological features of AD are strongly associated within the age 
group  of  75  year  olds  (Savva  et  al.  2009).  At  the  same  time  the  association  is  not  that  
evident in older people. People who died at the age of 95 and did not have dementia still 
had the pathological findings within their brains to those of AD patients which again 
underlines the many unresolved questions about this disease. Recent research has shown 
that healthy children of late onset AD patients have increased fibrillar amyloid burden in 
AD-vulnerable brain regions compared to controls but the meaning of this finding as a 
predictive risk factor for developing of the symptoms later on needs further clarification 
(Mosconi et al. 2010). 
2.2.1 Cholinergic Hypothesis of AD 
The cholinergic hypothesis states that the loss of cholinergic function in the central 
nervous system is associated with the cognitive symptoms in age-related memory 
dysfunction as in AD (Bartus et al. 1982). Accordingly, enhancement of signal 
transmission  in  nerve  synapses  can  be  used  as  a  treatment  strategy to  improve  impaired  
memory and other cognitive symptoms. This has been archived by inhibiting the catalytic 
site of cholinesterases which in turn prolongs the effect of the neurotransmitter 
acetylcholine in synapses. 
 
To date, cholinesterase inhibitors are regarded as the first line in pharmacotherapy for 
the  symptomatic  relief  of  mild  to  moderate  AD,  accounting  for  3  out  of  the  4  drugs  
currently approved for the treatment of the disease (Lleo et al. 2006, Farlow and 
Cummings 2007, van Marum 2008, Pepeu and Giovannini 2009). The effect of the 
cholinesterase inhibitors is moderate but they have been shown to improve cognitive 
functions of patients with mild to moderate AD which could also be seen in measures of 
daily living and behaviour (Birks 2006). Most of the studies on cholinesterase inhibitors 
have been conducted over a time period of one year or less which is too short of a time to 
evaluate true long term effects of these drugs. Rountree et al. (2009) evaluated the 
persistent treatment with dementia medication which consisted of either cholinesterase 
inhibitor alone or with memantine or memantine alone. Memantine is a NMDA receptor 
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(N-methyl-D-aspartic acid receptor) antagonist, the only non-cholinergic drug approved 
for  clinical  use  of  AD.  They  were  able  to  show significantly  slower  rates  of  decline  on  
measures of cognition and activities of daily living. The results were cumulative over time 
but more long term research needs to be done before cholinesterase inhibitors may be 
declared disease slowing compounds. So far other disease modifying therapy approaches 
have failed to show true efficacy in clinical trials which indicates that cholinesterase 
inhibitors will be the most important form of therapy in the near future (Golde et al. 2010). 
 
Recent findings have shown that the gene coding acetylcholinesterase (AChE) can 
form alternative variants of the protein, and interestingly the N-terminally extended 
synaptic form of AChE (N-AChE-S form) induces programmed cell death (Toiber et al. 
2008, Greenberg et al. 2010). This variant is over-expressed in AD which could explain 
the degeneration of cholinergic neurons in AD. Cholinesterase inhibitors were able to 
prevent this apoptotic effect of the N-AChE-S variant in preliminary studies which implies 
in a possibility of using cholinesterase inhibitors as preventive medication against 
neurodegeneration in AD. The catalytic properties of all studied AChE variants were 
similar. It is too early to conclude the real meaning of these findings but the preliminary 
results are intriguing. 
2.2.2 Amyloid Hypothesis of AD 
According to the amyloid hypothesis of Alzheimer’s disease amyloid-? peptide (A?) 
initiates the pathological cascade of the disease (Hardy and Higgins 1992, Hardy and 
Selkoe 2002). Amyloid-? peptides are 39 to 43 amino acids in length and cleave from the 
much larger transmembrane amyloid precursor protein (APP) (Selkoe 1999, Vassar et al. 
1999, Costantini et al. 2005). Amyloid-? peptides aggregate and form amyloid plaques 
which are extracellular abnormal protein deposits. The attempt to create disease modifying 
drugs has partly concentrated on boosting the clearance of amyloid?? peptides or 
preventing their aggregation. 
 
Recent findings have shown that in addition to its catalytic function, AChE can 
mediate other processes related to its peripheral anionic site (PAS), one being 
enhancement of amyloid aggregation and fibril formation (Alvarez et al. 1998, Giacobini 
2003b, Giacobini 2004, Inestrosa et al. 2008). AChE has been identified within amyloid-? 
deposits of both pre-amyloid diffuse deposits and mature senile plaques (Moran et al. 
1993, Geula et al. 1994). AChE forms stable complexes with amyloid plaques (Alvarez et 
al. 1998, Inestrosa et al. 1996). Stable amyloid-?-AChE complexes are more toxic than 
those formed without the effect of the enzyme (Alvarez et al. 1998, Munoz and Inestrosa 
1999, Reyes et al. 2004). It has been shown in APP-transgenic mice that release of AChE 
from ?-amyloid plagues improves memory impairment (Dinamarca et al. 2008). This 
translates to a strategy to create new kinds of acetylcholinesterase inhibitors inhibiting 
both catalytic and peripheral sites of the enzyme, which could relieve the symptoms of AD 
as well as modify the disease. Dual binding site inhibitors have been shown to inhibit the 
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AChE-induced ?-amyloid aggregation (Bolognesi et al. 2010, Camps et al. 2010). In 
addition, a monoclonal antibody that interacts with PAS of AChE has been shown to 
inhibit the promotion of amyloid fibril formation induced by AChE (Reyes et al. 1997). 
 
As long as there is no disease modifying treatment for AD, there will be debate over 
different hypotheses because complex neurodegenerative diseases like AD are affected by 
numerous factors. It has been widely established that amyloid-? is  involved  in  AD  
pathogenesis  but  is  it  the  sole  cause  of  the  disease  or  is  it  one  of  the  causes  or  even  a  
downstream consequence for something else, is still under debate (Pimplikar 2009, Young 
and Bennett 2010). 
2.3 Cholinesterases 
Cholinesterases are serine hydrolyzing enzymes that catalyze the hydrolysis reaction of 
choline esters (Fig. 1) (Soreq and Seidman 2001, Darvesh et al. 2003a). Cholinesterases in 
human central nervous system (CNS) are divided into two classes: acetylcholinesterase 
(AChE, EC 3.1.1.7) and butyrylcholinesterase (BChE, EC 3.1.1.8) (Fig. 2). The former is 
often referred as “true cholinesterase” whereas the latter “pseudo-cholinesterase”. 
 
 
 
Figure 1. Cholinesterases catalyze hydrolysis reactions of choline esters like neurotransmitter 
acetylcholine. Butyrylcholinesterase is less substrate specific than acetylcholineterase thus it also 
catalyze hydrolysis of more bulky substrates such as butyrylcholine. 
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Figure 2. The figures of A) Torpedo californica AChE (with acetylthiocholine in the figure, 
protein data bank (PDB) code 2C58) and B) human BChE (with butyrylthiocholine in the figure, 
PDB code 1P0P). 
 
2.3.1 Acetylcholinesterase 
 
Acetycholinesterase is an enzyme which plays a central role in neuronal signal 
transmission by regulating the synaptic concentration of the neurotransmitter acetylcholine 
(Fig. 2A) (Silman and Sussman 2005). Cholinergic neurons are rich in 
acetylcholinesterase and are present in all regions of the brain (Mesulam et al. 2002b). 
Acetylcholinesterase is a substrate specific enzyme that hydrolyses the natural substrate 
acetylcholine at one of the highest known enzymatic rates (Quinn 1987, Rosenberry 
2010). Acetylcholinesterase is evolutionally well preserved in different species, especially 
the active site of the enzyme and its function (Wiesner et al. 2007). 
 
The catalytic (also called acylation) site of AChE lies on the bottom of a deep gorge 
and is composed of three main amino acid residues: Ser-200 (serine), Glu-327 (glutamic 
acid) and His-440 (histidine) (Torpedo numbering) or Ser-203, Glu-334 and His-447 
(mammalian numbering) (Shafferman et al. 1992, Saxena et al. 1997, Johnson and Moore 
2006, Dvir et al. 2010). Anionic subsite consisting of Trp 84 (tryptophan), Tyr 130 
(tyrosine), Tyr 330 and Phe 331 (phenylalanine) (Torpedo numbering) or Trp 86, Tyr 133, 
Tyr 337 and Phe 338 (mammalian numbering), interacts with the quaternary 
trimethylammonium of acetylcholine, and positions the ester moiety at the acylation site. 
 
The peripheral anionic site (PAS) of AChE is composed mainly of five amino acid 
residues: Tyr-70, Asp-72 (aspartic acid), Tyr-121, Trp-279 and Tyr 334 (Torpedo 
numbering) or Tyr-72, Asp-74, Tyr-124, Trp-286, Tyr-341 (mammalian numbering) 
(Johnson and Moore 2006). It is practically located on the surface of the enzyme at the 
 
 
 
 
19
entrance of the gorge to the catalytic triad. Ligand binding to the PAS, change 
allosterically the conformation of the active center (Shafferman et al. 1992). Substrates 
entering  the  gorge  are  transiently  in  contact  with  PAS  which  traps  the  substrate  and  
enhances the efficiency of the catalysis. Non-classical functions of AChE are claimed to 
mediate through PAS of AChE (Johnson and Moore 2006). 
2.3.2 Butyrylcholinesterase 
Butyrylcholinesterase is a non-specific enzyme that hydrolyzes acetylcholine and other 
esters (Fig. 2B) (Masson et al. 2007, Masson et al. 2009). BChE is widely distributed in 
brain areas but it is also present in other tissues such as the liver (Li et al. 2000, Geula and 
Nagykery 2007). The physiological role of BChE is not known. Because of its non-
specific nature, BChE is involved in detoxification of harmful compounds in the human 
body (Masson et al. 2009). BChE expression varies during different developmental stages 
which implicates its role in neuronal development (Geula and Nagykery 2007). 
Similarities in the molecular characteristics of BChE in the AD brain and in the 
developmental stages of the brain suggest stimulation of a neuronal repairing mechanism 
involving BChE in degenerative disorders. Selective inhibition of BChE has been shown 
to increase cortical extracellular level of acetylcholine (Giacobini 2004, Greig et al. 2005). 
Conversely, BChE in the normal brain can hydrolyze acetylcholine if AChE is completely 
inhibited (Mesulam et al. 2002a). AChE knockout mice have dysfunctions in the central 
and peripheral cholinergic pathways but are able to survive to adulthood which indicates 
that BChE contributes to normal cholinergic transmission and serves as a back-up for 
AChE (Mesulam et al. 2002b). It is noteworthy that the level of BChE activity increases in 
AD whereas the level of AChE activity decreases (Giacobini 2003a). 
 
The active site of BChE is located in a gorge that is wider than the active site gorge of 
AChE (Saxena et al. 1997, Masson et al. 2009). The catalytic triad consists mainly of three 
amino acid residues: Ser-198, His-438, Glu-325 (Ser-226, His-466, Glu-353 human 
numbering) (Darvesh et al. 2003a). Two residues (Asp-70 and Tyr-332 mammalian 
numbering) where positively charged substrates bind before entering the gorge form the 
PAS of BChE. BChE lacks the PAS residues of AChE (Tyr-70, Tyr-121, Trp-279 Torpedo 
numbering; or Tyr-72, Tyr-124, Trp-286 mammalian numbering) which has been 
postulated  to  be  the  reason why BChE does  not  affect  amyloid  aggregation  in the same 
way that AChE does (Inestrosa  et  al.  2008,  Masson et  al.  2009).  On the  contrary,  the  C 
terminal peptide of BChE has been shown to interact with soluble forms of ?-amyloid and 
prolonging the kinetics of amyloid fibril formation (Diamant et al. 2006). 
2.3.5 Cholinesterase Inhibitors 
Currently approved cholinesterase inhibitors for the treatment of mild to moderate AD in 
Finland are galantamine, donepezil and rivastigmine (Fig. 3) (Fimea 2010). Tacrine was 
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the first FDA approved cholinesterase inhibitor for treatment of AD but poor 
bioavailability and adverse effects have limited its clinical usage (van Marum 2008). 
Cochrane review of 13 randomized, placebo-controlled, double blinded trials states that 
galantamine, donepezil and rivastigmine improve cognitive functions of patients with mild 
to moderate AD which could also be seen in measures of daily living and behaviour (Birks 
2006). The reviewer could not distinguish differences within clinical potency differences 
between these three compounds even though the modes of action are quite different. 
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Figure 3. The structures of the cholinesterase inhibitors on the market for AD in Finland. 
 
 
 
Traditional cholinesterase inhibitors including FDA approved (FDA, Food and Drug 
Administration in U.S.A.) donepezil, rivastigmine and galantamine inhibit primarily the 
catalytic  site  of  AChE,  and  some  of  them  also  inhibit  the  catalytic  site  of  BChE.  
Galantamine is a reversible competitive inhibitor of AChE (Camps and Munoz-Torrero 
2002, Darvesh et al. 2003b). It also inhibits BChE but its inhibitory potency toward this 
enzyme  is  four  fold  lower  than  for  AChE.  Donepezil  is  a  reversible  mixed  non-
competitive AChE inhibitor with 100 fold AChE selectivity over BChE. Rivastigmine 
inhibits AChE and BChE in pseudo-irreversible fashion i.e. it initially forms a covalent 
carbamyl complex with the enzymes that leads to a slow reactivation of the enzymes. The 
mechanism is common for cholinesterase inhibitors with a carbamate structure, including 
physostigmine. Rivastigmine and physostigmine inhibit AChE and BChE non-selectively 
if potencies are calculated using IC50 values (IC50, concentration yielding 50% inhibition) 
(Giacobini 2004). Darvesh et al. (2003b) calculated a second order rate constant which 
takes into account the pseudo-irreversible mode of action of these compounds and came to 
the conclusion that selectivity of rivastigmine is 100 fold higher towards BChE compared 
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to AChE, whereas selectivity of physostigmine is 3 fold higher towards BChE compared 
to AChE. 
 
Propidium which is an inhibitor that binds to the peripheral anionic site of AChE is 
able to inhibit AChE induced ?-amyloid aggregation (Bartolini et al. 2003). Donepezil and 
physostigmine show slight inhibitory potential for AChE induced ?-amyloid aggregation 
whereas tacrine is inactive. Series of inhibitors designed to bind to both sites of AChE 
have been shown to act as dual inhibitors that inhibit AChE-induced ?-amyloid 
aggregation as well as catalytic action (Bolognesi et al. 2010, Camps et al. 2010). BChE 
has not been associated with ?-amyloid aggregation in the same way as AChE is. The C-
terminus of BChE has been attenuated to prolong the amyloid fibril formation therefore 
butyrylcholinesterase inhibitors should not interact with it (Diamant et al. 2006). 
 
In addition to classical inhibitory effect, cholinesterase inhibitors may have other 
biological activities, e.g., galantamine modulates nicotinic acetylcholine receptors in a 
non-competitive fashion which potentiates the channel activation by the natural transmitter 
and leads to increased pre-synaptic release of acetylcholine (Storch et al. 1995). 
Physostigmine has similar nicotinic acetylcholine receptor modulating properties as 
galantamine. Donepezil has been shown to inhibit ?-secretase in vitro (Mancini  et  al.  
2007). Huperzine is a potent cholinesterase inhibitor which also has neuroprotective 
potential through inhibition of apoptosis, beneficial actions on A? processing and it 
reduces oxidative stress (Zhang and Tang 2006). 
 
In general, multifunctional compounds that could modify the progression of AD in 
addition  to  the  classical  mode  of  cholinesterase  inhibition  have  become  a  hot  area  of  
interest. Most often new compounds aim to also target the peripheral site of AChE to 
decrease amyloid aggregation (e.g., Bolognesi et al. 2005, Dickerson et al. 2005, Munoz-
Ruiz et al. 2005a, He et al. 2007, Kwon et al. 2007, Camps et al. 2008, Leon et al. 2008, 
Marco-Contelles et al. 2009, Rizzo et al. 2010). Other approaches aim to find compounds 
that inhibit ?-secretase (Zhu et al. 2009), scavenge free radicals (Decker et al. 2008, Spuch 
et al. 2010) or activate muscarinic M1 receptors (Fang et al. 2010). One of the groups has 
taken a further step by creating a true multi-potent compound, memoquin, which inhibits 
AChE, AChE-mediated amyloid aggregation, ?-secretase, tau-phosphorylation and free 
radical formation, also in vivo (Bolognesi et al. 2009). It will be interesting to see if such a 
compound could reach clinical trials or is the effect non-selective also for unwanted 
targets. 
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2.4. Cholinesterase Inhibitors from Natural and Synthetic Origins 
2.4.1 Drug Discovery Process 
The drug discovery and development process is a long and costly road from target 
identification to the market. It begins with basic research and identification of a target 
relevant to a disease and ends up with a new molecular entity that has been through 
preclinical and clinical phases and has been formulated into a product that is marketed to 
patients. The whole process takes ca. 13.5 years on average and costs 0.9 billion dollars 
per new molecular entity launch (Paul et al. 2010). Costs have been increasing 
exponentially since the 1950s at the rate of 13% a year (Munos 2009). Withdrawal rates 
are high in phases II and III, therefore nine compounds are need to enter clinical phase I to 
yield one new molecular entity launch. Clinical trials are the most expensive phases in the 
whole process accounting for around 63% of the costs (Paul et al. 2010). Therefore, 
improving the quality of research in the preclinical phase saves money and years of work 
if non-drug-like compounds are cut out of the pipeline as early as possible. The number of 
drug approvals has been a decreasing trend which raises concerns for public health care 
systems. The number of FDA drug approvals in 2009 was 26 (Hughes 2010) whereas the 
number of drug approvals in Europe was 29 (Eichler et al. 2010). 
 
The drug discovery process can be roughly divided into four phases: i) target selection 
and validation, ii) assay selection, development and adaptation, iii) primary and secondary 
screening in vitro and iii) lead discovery and optimization (Fig. 4) (Johnston and Johnston 
2002, Mayr and Bojanic 2009). When designing a screening campaign on a selected target 
the first  decisions to be made are the selection of assay,  the format of the assay and the 
detection method. High-throughput screening (HTS) is defined by the number of data 
points created per day; typically 10,000–100,000 compounds are assayed per day. Assay 
applicability for large scale screening limits the materials to be screened and vice versa. If 
tens of thousands of compounds or extracts are to be screened, the format of the assay 
should be in the low microlitre scale and automatable. A screening campaign for more 
targeted libraries leaves more options for assay formats. When screening extracts, it is 
wise to couple liquid chromatography separation technique to the bioactivity assay of 
choice (Wagenaar 2008). This enables the tracking of activity to a certain compound or 
fraction containing a low number of compounds which helps the following purification 
and structure elucidation steps. Complexity of the sample decreases with the fractionation 
which is advantageous because some compounds can mask detection in subsequent 
bioactivity measurements. 
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Figure 4. Schematic presentation of the drug discovery process represented from the perspective 
of this thesis. This thesis covers in vitro screening of the natural product and commercial synthetic 
compound libraries to create hits, as well as the assay development aspects for enzymatic targets. 
Target validation, medicinal chemistry and lead discovery parts were not dealt in this thesis 
(represented with dashed lines). General process was modified from Johnston and Johnston 2002, 
Potterat and Hamburger 2006, May and Bojanic 2009. 
In the assay adaptation phase, the assay is optimized to the screening set-up and 
validated for the specific environment which usually includes miniaturization of the assay 
and validation of the automatic liquid handling robotics (Mayr and Bojanic 2009). 
Statistical parameters are used for assay validation to ensure robustness of the assay and 
discrimination of the signal from the background (Zhang et al. 1999, Bollini et al. 2002). 
The screening window coefficient (Z’-factor), signal-to-background (S/B) and signal-to-
noise (S/N) ratios are common validations parameters. 
In  the  primary  screening  phase  the  target  is  usually  assayed  using  a  single  
concentration of the compounds (Keseru and Makara 2006). A hit limit is set, e.g., 3xSD 
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or 4xSD (SD, standard deviation) from the average to identify the compounds that cause 
an effect that significantly differs from the mean signal. In the secondary screening phase, 
several concentrations are used to evaluate dose-dependency of the hits in the primary 
screening. In addition, effects on other related targets can be assessed to evaluate 
selectivity. Preliminary toxicological evaluation in an in vitro set-up at this stage is wise 
because toxicological effects are among the main reasons for attritions in clinical phases 
(Paul et al. 2010). Prediction of drug-likeness is central in drug discovery. Selection of hits 
for lead optimization should be based on potency and drug-likeness because compounds 
entering the lead phase should have properties that ensure the bioavailability of the 
compound (Di et al. 2009). Solubility, permeability, metabolic stability and interactions 
with active transporters should be evaluated before any compound proceeds further along 
the pipeline as drug candidates. Rapid metabolism and high efflux by transporters can lead 
to short half-life, high clearance and inadequate efficacy which in turn lead to low 
bioavailability of the drug. 
 
The lead discovery and optimization phase aims to improve the hit quality towards a 
lead and further a clinical candidate (Keseru and Makara 2009). The main goals are to 
improve, e.g., potency, biological availability and pharmacokinetic properties of the hits. 
In the analysis of Keseru and Makara (2009), several differences were found in the 
comparison of the hits in HTS screenings and corresponding leads. Lead potency, 
lipophilicity and molecular mass are increased compared to hits. In addition, lead 
structures are more complex and more flexible than hits. The leads derived from the hits 
discovered in HTS are not necessarily optimal drug candidates. In comparison, old leads 
published before year 2000 are less lipophilic. Increased lipophilicity has been postulated 
to be one of the reasons for high attritions in clinical trials. The optimal properties of each 
drug are a fine balance between multiple factors (Waring 2010). Lipophilicity is one of the 
key factors because it affects almost all aspects of drug behaviour within the body, e.g., 
solubility, toxicity, efficacy, bioavailability and metabolism. Chemical modifications of 
the hits affect also the metabolic stability of compounds which can be taken into account 
in drug development to increase bioavailability and the half-life of the drug candidates 
(Nassar et al. 2004). This can be achieved, e.g., by modifying metabolically active groups 
that are vulnerable to metabolic enzymes and by decreasing lipophilicity. 
2.4.2 In vitro Screening of Cholinesterase Inhibitors 
The Ellman’s reagent based assay (Ellman et al. 1961) is by far the most widely used in 
the area of measuring cholinesterase activity. It is applicable for isolated AChE and BChE 
as well as for homogenated tissue samples. The assay has been used in cuvette and 96-well 
plate formats but also on thin layer chromatography (TLC) plates (e.g., Rhee et al. 2001) 
and in an on-line with high performance liquid chromatography (HPLC) coupled to a 
biological detection set-up (Ingkaninan et al. 2000). The substrate (ATCI, 
acetylthiocholine) reacts with the enzyme and the formed product further reacts with 
dithionitrobenzoate (DTNB, also called Ellman’s reagent) to form a yellow anion. 
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Inhibitors decrease the formation of the coloured product which can be detected 
photometrically or visually on TLC. On TLC the yellow colour is not convenient because 
of the low contrast between the yellow colour and white plate. Marston et al. (2002) 
developed an assay on TLC that uses napthyl acetate as a substrate and Fast blue salt B as 
a reagent. The product is purple which increases the contrast and eases visual detection of 
inhibitors in the sample. Both of these assays are compatible with natural products, either 
extracts or pure compounds, and synthetic compounds but the assay set-up can limit their 
usefulness in screening especially when increased throughput is required. Ellman’s 
reagent based assay in micro-well plate format can be adapted to an automated 
environment which enables its usage when high throughput is required. The following 
paragraphs discuss and evaluate the pros and cons of different libraries used in the 
screening process of drug discovery. 
2.4.2.1 Natural Products 
Natural products have been an undeniable success story in drug discovery historically but 
also during the past three decades (Newman et al. 2003, Newman and Cragg 2007). Half 
of the drugs approved for the market during 1981–2006 are either direct isolates from 
nature or their semi-synthetic derivatives or proteins or molecules otherwise related to 
natural sources. In spite of this, problems in adapting natural products into HTS platforms 
like low throughput in screening and pitfalls in the handling of extracts are issues that 
have been resulted in a decreased interest in natural product research (Eldridge et al. 
2002). In addition, natural compounds are often more challenging to produce in large 
quantities than synthetic compounds because extraction, separation and structure 
elucidation processes are considered laborious and time consuming. Development of high-
throughput platforms for large libraries has led to the usage of synthetic compounds 
produced by combinatorial chemistry over natural products in industrial screens (Li and 
Vederas 2009). Despite the huge expectations loaded on large random screens of hundreds 
of thousands synthetic compounds, the number of approvals for synthetic entities has not 
increased with the increase in throughput. Development of analytical techniques like 
liquid chromatography coupled to nuclear magnetic resonance spectroscopy (LC-NMR) 
and multi-dimensional-NMR, in particular, and the down-scaling of the amount of sample 
needed, are elements that will attract pharmaceutical companies back to natural product 
research (Eldridge et al. 2002, Wolters et al. 2002, Lambert et al. 2005, Lambert et al. 
2007, Lang et al. 2008, Lin et al. 2008, Queiroz et al. 2009). 
 
As an example of the development of analytical techniques, amounts as low as 7 to 50 
µg of a new compound is enough for structure elucidation by 1D and 2D proton-NMR 
analyses in new microcoil flow probes compared to several milligrams needed in 
traditional NMR analyses (Eldridge et al. 2002, Dalisay and Molinski 2010). At its best, 
fractionation of 700 µg of an extract using analytical scale HPLC run into microtiter plates 
has been shown to be sufficient for both structure elucidation and biological assay if 
spectral data are combined and analyzed with the help of database information (Lang et al. 
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2008). UV and MS analyses of fractions in combination with NMR analysis using a 
capillary NMR probe are powerful tools for quick structure elucidation. Quantitation of 
nanomole amounts of compounds by NMR is also possible which further stresses the 
importance of the new NMR techniques in natural product drug discovery (Dalisay and 
Molinski 2009). Quantitative nuclear magnetic resonance spectroscopy (qNMR) does not 
necessarily require analytical standards for quantitation which is a huge advantage over 
other quantitative techniques like HPLC-UV (UV, ultra violet) (Lubbe et al. 2010). 
 
Natural product scaffolds are more complex in structure than synthetic drugs or 
compounds in synthetic compound libraries (Lee and Schneider 2001, Feher and Schmidt 
2003, Ortholand and Ganesan 2004, Newman 2008, Rosen et al. 2009, Sukuru et al. 
2009). The complexity of natural products is mostly due to polycyclic structures, 
heterocyclic substituents and multiple chiral centers but also the size and lipophilicity 
differ from compounds in synthetic libraries. High numbers of trade drugs are of natural 
origin (Newman et al. 2003, Newman and Cragg 2007) which can also be seen by 
comparing properties of natural products, trade drugs and synthetic compounds in libraries 
where trade drugs resemble more natural products than the combinatorial compounds do 
(Feher and Schmidt 2003). In addition, combinatorial compounds are more flexible than 
natural compounds which have been postulated to decrease their specificity and activity. 
The connections in combinatorial compound ring systems are established by single bonds 
between them whereas natural ring systems are rigid and have few routable bonds. Lee 
and Schneider (2001) analysed the ring scaffolds in a set of natural products and compared 
them to trade drugs and found that only 17% of the scaffolds found in natural products are 
present in trade drugs. Importantly, differentiation of biologically relevant chemical space 
from general chemical space gives more power to predictions of biological activity 
(Larsson et al. 2007). Natural product scaffolds are well represented in regions of 
biologically relevant chemical space that is rarely occupied by synthetic compounds 
(Rosen et al. 2009). There is a huge pharmaceutical potential in diverse ring systems of 
natural origin which is also acknowledged by industry (Drewry and Macarron 2010). 
 
In general, nature has been a good source to find cholinesterase inhibitors. One of the 
three cholinesterase inhibitors on the market today, galantamine, is a direct isolate of 
plants belonging to Amaryllidaceae species such as Leucojum spp. L., Narcissus species 
or Galanthus spp. L. (Heinrich and Lee Teoh 2004). This drug was found based on 
ethnopharmacological knowledge from the Caucasus mountain range and Eastern Europe. 
The association to AChE inhibition was established in the 1960s but it was licensed only 
during the year 2000 for the treatment of AD. 
 
Another well known cholinesterase inhibitor from a natural source is physostigmine 
isolated from Physostigma venenosum (Balf.) (Zhao et al. 2004). Its narrow therapeutic 
index and short half-life have limited its medicinal usage (Camps and Munoz-Torrero 
2002, Coelho and Birks 2001) but the compound is extensively used as a reference 
compound in enzymatic assays. The carbamate analogue of physostigmine, rivastigmine, 
has been approved for the market for AD treatment (Polinsky 1998, Jann 2000). 
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Huperzine isolated from the Chinese plant Huperzia serrata (Thunb. ex Murray) Trev., 
is  at  the  clinical  phase  of  development  (Ma  et  al.  2007).  In  addition  to  cholinesterase  
inhibition, huperzine has shown neuroprotective potential against apoptosis, beneficial 
actions on A? processing and a reduction of oxidative stress which makes this multi-
targeted compound highly interesting as a future treatment option (Zhang and Tang 2006). 
The primary results are encouraging but large trials with standardized products still needs 
to be conducted (Desilets et al. 2009). Some of the clinical trials have estimated the effects 
of plant extracts that were not standardized. 
2.4.2.2 Natural Product Libraries for Screening 
Large and small scale natural product libraries consisting of either pure isolated 
compounds or extracts have been used successfully in screening campaigns against 
various isolated or cell-based targets (Eldridge et al. 2002, Wagenaar 2008, Jayasuriya et 
al. 2005, Shaneyfelt et al. 2006, Bugni et al. 2008, Lee et al. 2008, Salam et al. 2008a, 
Hashimoto et al. 2009, Hung et al. 2009). 
 
The number of isolated compounds in natural pure compound libraries in the literature 
is most often in the region of hundreds, e.g., 280 compounds (Shaneyfelt et al. 2006), 200 
compounds (Salam et al. 2008a) or 400 compounds (Hung et al. 2009) which diminishes 
the throughput in screening. In principle, there are no limitations in possible compound 
amounts in natural pure compound libraries due to the fact that thousands of compounds 
can be isolated within months (Bindseil et al. 2001). In practice, isolation procedures 
increase expenses of this approach extensively prior the actual bioactivity phase when the 
number of compounds increases to thousands. On the other hand, the following stages 
from hit to a validated lead are significantly easier and less expensive than working with 
extracts. For pharmaceutical companies that routinely screen the same library for tens of 
targets, this approach may well be cost-effective also at a larger scale. It is noteworthy that 
a natural pure compound library has been shown to produce significantly higher hit-rates 
when nine targets were evaluated compared to a synthetic compound library (Bindseil et 
al. 2001). Natural pure compounds are routinely included as a part of huge chemical 
libraries of millions of compounds in pharmaceutical companies from which a subset of 
compounds  is  selected  for  each  screen  (Sukuru  et  al.  2009).  If  structure  diversity  is  a  
selection criterion for a certain screen, a large fraction of natural products is usually 
selected because of their inherent chemical diversity. 
 
Screening of large crude extract libraries of thousands of extracts is another approach 
in the screening of natural products. Generally this is not considered the best option. The 
properties like viscosity can interfere with automatic liquid handling, compounds can 
mask each other’s activities, and some of the compounds can interfere with assays and 
raise the false positive or false negative rates (Wagenaar 2008, Bindseil et al. 2001). These 
issues lower the quality of the hits. Nevertheless, screens of 1400 extracts (Lee et al. 
 
 
 
 
28
2008), 64 000 extracts (Jayasuriya et al. 2005) and even over 110 000 extracts have been 
conducted in which target specific active constituents have been identified after bioactivity 
guided fractionation of the active extracts. 
 
Pre-fractionation of extracts has been an option in natural product screening to 
simplify the complexity of the screened extracts and to avoid the above mentioned 
problems. Most often pre-fractionation is achieved through coupling reversed-phase 
HPLC (RP-HPLC) separation techniques to an automated fraction collector (Eldridge et 
al. 2002, Wagenaar 2008, Bugni et al. 2008). Typically, fractions contain several 
compounds e.g. 1–5 compounds per fraction, and before structure elucidation more 
detailed separations of the compounds in the active fraction is required. Alternatively, LC-
MS (MS, mass spectroscopy) and LC-NMR techniques can be utilized on-line with 
fractionation while part of the eluent is split and directed to spectroscopic detection which 
gives preliminary data on the number of the compounds present and their structures. 
Bioactivity of each compound has to be assayed separately. Large pre-fractionated 
libraries have been conducted from microbial, plant and marine sources which can contain 
up to 200 000 fractions (Eldridge et al. 2002, Wagenaar 2008, Bugni et al. 2008). 
 
As proven with synthetic compound libraries, high throughput and an increase in the 
number of compounds in screening campaigns do not necessarily result in higher numbers 
of validated leads. This also applies for natural products. The possibility to target the 
library based on a prior knowledge is an advantage for natural products. Natural products 
have been used in traditional healing for centuries which is a rich source of information 
that can be applied in screening strategies to narrow down the screening material in the 
library from random to a more targeted set of compounds or extracts. This approach is also 
known as ethopharmacological knowledge. Probability in detecting a certain bioactivity is 
higher if relative traditional use has been reported for the natural product, e.g., in case of 
antifungal activity (Svetaz et al. 2010). The probability to find antifungal activity was 40% 
if traditional use was reported for the assayed plant compared to 20% probability for 
random plant selection. In addition, detected potencies were higher in the group with an 
ethnopharmacological background. Derived from a prior knowledge of bioactivity or a 
bioactive compound in a specific species, the screening set-up can be broadened to cover 
phylogenically related species. Furthermore, knowledge of biosynthetic routes, 
chemotaxonomy and similarity of compounds in unrelated species are means to target 
material. 
2.4.2.3 Synthetic Compound Libraries for Screening 
Design of synthetic compounds for synthetic compound libraries is directed to cover a 
broad chemical space and to make compounds drug-like. Drug-like traditionally translates 
into compound properties which fit with the Lipinski rule of five (Lipinski et al. 1997). 
This rule uses computational and experimental approaches to predict solubility and 
permeability of a compound through physical bi-layer membranes and ultimately the 
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human body after oral delivery. Prediction of permeation is crucial in drug discovery 
because even the most promising compound is worthless if it cannot reach the target in the 
body and cannot be used as a drug. Basic rules are as follows: i) number of H-donors 
should not exceed 5; ii) number of H-acceptors should not exceed 10; iii) molecular 
weight should not exceed 500; iiii) calculated LogP should not exceed 5. The lipophilicity 
limit has been shown to be dependent on the molecular weight in a way that the lower the 
weight the lower lipophilicity limit should be for the compounds (Waring 2009). 
 
Several errors may occur in screening if the compounds’ drug-likeness is not 
considered early on (Di et al. 2009). It is an advantage in synthetic compound library 
design that these properties may be considered. Solubility is one of the most important 
issues because it affects results in in vitro assays and in vivo. In vitro, potency of poorly 
dissolving compounds may be artificially low which reflects structure-activity relationship 
(SAR) determinations and decision making when choosing compounds for further studies. 
Toxicity may also be underestimated. In vivo, poorly soluble compounds have poor 
bioavailability and variation between subjects and species may be substantial. Studies on 
compounds in the HTS libraries reveal that 30% of the compounds have solubility less 
than 10 ?M in biological assays. The problem has been acknowledged in pharmaceutical 
companies and nowadays drug-likeness is assessed before in vivo studies. 
 
Designing a library can be derived from several perspectives. Drug-likeness and 
preferable ADME properties are main strategies for creating synthetic compound libraries 
(Goodnow et al. 2003). A design that aims to create a more focused set of compounds 
based on the target dimensions can lead to better hit-rates. Computational technologies 
have emerged to make the library design more efficient and cost-effective (Balakin et al. 
2006). Structure-based design, pharmacophore model and fragment based topological 
information combined to combinatorial chemistry can yield potential ligands for 
therapeutic targets. An example of a targeted approach in synthesizing a chemical library 
is to select a certain structural core that is known to have activity against a specific target 
or to have interaction with the target, and create derivatives or mimics of this structure 
(Birks 2006, Best et al. 2004, Bhatia et al. 2010, Shih et al. 2010). The goal is to cut down 
the size of the library and increase the hit rate. As an example, the ?-lactam scaffold has 
been used to create a highly diverse combinatorial library of compounds that meet the 
criteria for drug-likeness (Steger et al. 2001). 
 
Diversity-oriented synthesis of compounds aims to fill chemical space occupied by 
natural products which are inheritably diverse and “designed by evolution” to interact with 
three-dimensional natural surfaces, or to fill new unexplored areas of chemical space 
(Cordier et al. 2008, Spandl et al. 2008). Another important goal is to be able to synthesize 
compounds efficiently without compromising the diversity requirements. The realization 
that compounds created with traditional combinatorial chemistry lack the complexity and 
diversity of natural products has led to the new era of trying to combine the best of both 
by means of using natural templates in combinatorial chemistry set-ups or to mimic the 
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chemical space of natural compounds in combinatorial synthesis (Ortholand and Ganesan 
2004, Nielsen 2002). 
 
Natural product scaffolds have been characterized to form scores that allows the 
characterization of synthetic compounds for their “natural product-likeness” with the view 
to broaden the chemical space of combinatorial compounds (Lee and Schneider 2001, Ertl 
et al. 2008). Diversity-oriented synthesis differs from target oriented combinatorial 
synthesis in aiming to cover wider chemical space (Cordier et al. 2008). The aim is to keep 
synthesis of highly diverse compounds simple. Assembly of a small molecule library 
should have up to 5 synthetic steps. Extending the combinatorial chemistry approach to 
complex natural products creates highly diverse sets of compounds that have the scaffold 
from natural compounds but is substituted with additional groups. Further challenges arise 
from requirements to synthesize skeletally diverse compounds inspired by nature that 
would be structurally unique. It remains to be seen if these approaches will lead to higher 
hit rates in screening campaigns in the future. Better knowledge on synthesis of complex 
compounds will aid further in the synthesis of “real” natural compounds at an industrial 
scale because the reliable access and supply of rare natural materials for isolation of highly 
potent compounds directly from nature is often a problem that has to be solved before 
commercialization of the product (Li and Vederas 2009). 
 
When creating chemical libraries by means of combinatorial chemistry lots of closely 
related compounds are created (Metzger et al. 2006). In the secondary phase of screening 
the activity data of these compounds can be used in quantitative structure activity 
relationship determinations (QSAR). Statistical analysis of bioactivities in modularly 
assembled libraries conducted with a computational program aid in creating trends 
between structures and activities (Seedhouse et al. 2010). Further, the data reveal features 
that are important for activity which can be used in the design of second generation 
compounds. 
 
Synthetic chemical libraries have been screened successfully for loads of novel 
enzyme inhibitors with high potency (Batra et al. 2002). Carbonell et al. (2000) identified 
nine selective inhibitors of acetylcholinesterase from a small combinatorial library of 100 
compounds. Also, other strategies to find new AChE inhibitors exist, e.g., Kapková et al. 
(2005) utilized random chemistry where tacrine derivatives were created by irradiating 
tacrine in different solvents which leads to radical recombination and formation of new 
derivatives. 
2.4.3 In vitro Screening as a Basis for In silico Predictions 
Virtual screening can be divided into two approaches: i) similarity based screening in 
which compounds known to bind to the target are used as structural queries for the model 
and ii) automated docking of compounds into the target binding site when the 3D structure 
of the target is known (Lengauer et al. 2004, Taft et al. 2008). In similarity based screens 
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no information on the structure of the target is needed. Quality of the similarity based in 
silico screen is based on the results from in vitro screens which highlights the importance 
of selecting the data.  Data sets  from the literature can also be used to test  the predictive 
value of the docking model by comparison of the predicted potency values (e.g. IC50 
values) from automatic docking assay to observed ones (Bernard et al. 1999, Recanatini et 
al. 2000, Sippl et al. 2001). The computational model for biological activity can be as 
good as the quality of the observed biological data (Cronin and Schultz 2003). 
 
Often the data sets are collected from several publications which increase the 
possibility of an error if the selection process is not done carefully (Cho et al. 1996, Lv 
and Xue 2010). Differences in results produced with different assays are acknowledged 
but not so much in modifications of the same assay. By taking a closer look into the 
screening of acetylcholinesterase inhibitors, the literature is full of “minor” modifications 
of the Ellman’s reagent based assay for the measurement of acetylcholinesterase activity 
(Ellman et al. 1961) (Appendix 1). Variations include enzyme, substrate and reagent 
concentrations and assay parameters, e.g., temperatures, measurement wavelengths, 
measurement times and incubation times. 
 
In addition, acetylcholinesterase can be isolated from humans, invertebrates and 
mammalians. The amino acid sequence of acetylcholinesterase is dependent on the origin 
of the enzyme (Wiesner et al. 2007, Khan 2009) which also affects the kinetic constants of 
acetylcholine and other substrates as well as inhibitors (e.g., Ellman et al. 1961, Vellom et 
al. 1993, Contreras et al. 1999, Sauvaitre et al. 2007). The sequence similarity is high 
which  makes,  e.g.,  AChE  isolated  from  the  eel  a  good  model  system  to  screen  AChE  
inhibitors. Nevertheless, the differences should be taken into consideration when creating 
an in silico prediction. AChE isolated from human erythrocytes and human recombinant 
AChE have been shown to have the same affinity for acetylthiocholine which makes 
results from these two enzymes being comparable when using this substrate (Darvesh et 
al. 2003b). When creating an in silico model, the data from several enzyme sources can be 
separately evaluated in their own data sets after which a comparison of the alignment of 
active compounds can give additional information on selectivity (Dimoglo et al. 2001). An 
example  on  the  effect  of  the  variant  of  the  same  assay  is  potency  of  physostigmine  for  
AChE: the observed IC50 value for physostigmine was reported to be 0.69 nM with pre-
incubation and 340 nM without pre-incubation when a mouse brain homogenate was used 
as the enzyme source (Sugimoto et al. 1990) whereas with 20 min pre-incubation of 
physostigmine with human erythrocyte AChE led to an IC50 of  19  nM (Villalobos  et  al.  
1994). Based on these observations, the minor modification of the assay can barely be 
called “minor” if it causes major changes in the potency evaluation in the order of a 500-
fold difference. 
 
Attempts to ensure, if even possible, compatibility of the data sets collected from 
several publications have been made by several means. Comparison of activity values of 
the reference compounds assayed under the same conditions is probably the most obvious 
way (Bernard et al. 1999, Cho et al. 1996). This leads to a problem in comparing the assay 
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conditions if each group modifies the assay (Appendix 1). Using results from papers 
published by a certain group which have screened lots of compounds probably ensures the 
most similarity in terms of the assay conditions (Dimoglo et al. 2001, Saracoglu and 
Kandemirli 2008, Gupta and Mohan 2010). Ideally high quality data should be generated 
by the same lab and the same person with exactly the same protocol (Cronin and Schultz 
2003, Scior et al. 2009). At the worst, the combined data from several publications are not 
comparable and even at the best are subject to significant variation. 
 
Many times confirmation of the assay conditions in publications is not possible 
because the authors may just refer to the original publication but do not specify which 
variant of the assay in the original paper was used or leave out information concerning 
assay conditions (Atta-ur-Rahman et al. 2001, Kang et al. 2001, Cardoso et al. 2004, Zhan 
et al. 2010). In the original paper for assaying acetylcholinesterase activity, Ellman et al. 
(1961) investigated kinetic profiles of several substrates, initiated the reaction with both 
enzyme preparation and substrate, and utilized tissue homogenates and purified enzymes 
as sources for cholinesterases. If authors refer to the original publication without 
specification of the conditions the information is incomplete and misleading. Lv and Xue 
(2010) classified AChE inhibitors and non-inhibitors according to potencies collected 
from 21 literature reports and characterized molecular descriptors by machine learning 
methods. A closer look at the data collected from the literature reveals that IC50 values are 
defined mostly with Ellman’s assay but the assay conditions vary substantially. The 
enzyme sources vary from human and bovine erythrocytes, mouse and rat brain 
homogenates  to  eel,  whereas  the  substrate  concentrations  vary  from 0.2  mM to  4.8  mM 
and also other conditions are not the same. One reference included in the data set even 
uses another assay for determination of AChE inhibitory effect. The predictive accuracy of 
the created model was low (76.3 – 88.0%) which could be explained, at least partly, with 
the poor quality of the original data set due to incomparable IC50 values. 
 
When creating high quality in vitro data the assay should be validated by means of 
statistical parameters that measure variation and signal window width to ensure 
discrimination of background deviation from the signal (Zhang et al. 1999, Bollini et al. 
2002). None of the references mentioned in Appendix 1 include validation data in spite of 
the numerous modifications mentioned. Nevertheless, the data have been used to create 
computational models to predict biological activity which raises the question of the quality 
of these in silico models (Dimoglo et al. 2001, Saracoglu and Kandemirli 2008, Gupta and 
Mohan 2010). 
 
Virtual screening and HTS can be used separately but at the best they complement 
each other. A preliminary in silico screen can substantially diminish the number of data 
points needed in in vitro screens and at the same time increase the hit rate (Entzeroth 
2003, Bajorath 2002, Stahura and Bajorath 2004, Han et al. 2008). Natural product 
libraries are also used in virtual screening to limit the number of compounds which are 
then evaluated in in vitro assays (Salam et al. 2008b). Also, acetylcholinesterase inhibitors 
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have been successfully screened using combination of virtual screening, docking and in 
vitro studies (Rollinger et al. 2005, Schuster et al. 2010). 
 
Iterative similarity based screen utilizes a small set of in vitro data to create a docking 
model (Lengauer et al. 2004, Plewczynski et al. 2009). A second small set of compounds 
similar to the most active ones in the first cycle is then assayed and docked in the model to 
train it. The same cycle can be repeated as long as necessary to create actives working in 
the nanomolar range. In one-shot screening, a large chemical library is first assayed in 
vitro for activity and the data are used for creating the docking model (Gupta et al. 2011). 
 
Established ligand-protein complexes can be a basis for creating a pharmacophore 
based docking model that uses information on biologically active conformation of the 
known inhibitors (Sopkova-de Oliveira Santos et al. 2010, Zaheer-ul-Haq et al. 2010). 
Combination of results from several docking algorithms can create a representative model 
for screening (Zaheer-ul-Haq et al. 2010). The top scored conformations from the first 
algorithm are rescored with a second algorithm to increase the predictivity of the model 
and so on. Pharmacophore model based virtual screening has proven to be a powerful tool 
for finding new AChE inhibitors (Sopkova-de Oliveira Santos et al. 2010). The top score 
compounds in virtual screening had low-nanomolar potency when assayed in vitro. AChE 
is a complex and flexible enzyme system which in turn complicates the in silico modelling 
of substrate and inhibitor interactions with the enzyme (Khan 2009, Lushington et al. 
2006). The best predictions and detailed factors affecting binding are from hybrid methods 
that combine several approaches to compensate for each other’s shortcomings. As an 
example, including data on ligand-protein crystallographic complexes to the docking 
algorithm improves the correlation between observed and predicted data (Guo et al. 2004). 
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3 Aims of the Study 
The main aim of the study was to assess the applicability of in-house chemical libraries for 
screening purposes. The libraries consisted of plant and fungal extracts, natural coumarins 
with their synthetic derivatives, and synthetic compounds. Further, to achieve the main 
aim, two cholinesterase inhibitory assays were adapted to appropriate formats for the 
screening of each library. 
 
The specific aims were: 
 
1) to critically evaluate the applicability of the two assays used in this contribution as 
screening tools for cholinesterase inhibitors (I–V). Assay performance was 
assessed using controls and statistical parameters which work as indicators for the 
quality of the assays. 
 
2) to assess the fungal and plant extract libraries as sources for cholinesterase 
inhibitors (I, II). Special features of extract library screening were addressed, 
mostly through coupling of analytical separation techniques to biological assays. 
 
3) to assess the small coumarin and large synthetic compound libraries as sources for 
cholinesterase inhibitors (III, IV). Adaptation of the assay formats to low-
throughput screening and to high-throughput screening set-ups were evaluated. 
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4 Experimental 
4.1 Materials 
4.1.1 Fungal Cultures and Extraction (I) 
Mycelia of studied fungi were grown in low nitrogen liquid media for 8 weeks at +28°C. 
The growth media (600 ml) was extracted with ethyl  acetate (3 x 200 ml).  Ethyl  acetate 
fractions were collected, combined and evaporated to dryness. All screened fungi 
belonged to the group of wood rotting fungi (Table 1 in I). 
 4.1.2 Plant Material and Extraction (II) 
Mentha longifolia L., M. pulegium L., M. arvensis L., M. × gentilis L., M. × piperita L. 
var. officinalis, M. spicata L. and M. spicata L. var. crispa Benth (Lamiaceae) were 
cultivated in Mikkeli, Finland and harvested in August 2000 after a growth period of two 
years (M. longifolia, M. pulegium) or three years (M. arvensis, M. × gentilis, M. × piperita 
var officinalis, M. spicata, M. spicata var crispa) and identified by Bertalam Galambosi, 
senior research scientist at the Agrifood Research Centre, Finland (II). 
 
Air-dried plant material was extracted in 80% methanol (MeOH) (aq) under sonication 
according to Rauha et al. (2000). Different species as well as different parts of plants i.e. 
flowers, leaves, stems and roots were extracted separately. 
4.1.3 Coumarin Library (III) 
From the studied coumarin library (Fig. 5, Table 1) coumarins 1–24 are of natural origin 
whereas coumarins 25–29 are synthetic derivatives of coumarins. 
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Table 1. The coumarin library and sources of the compounds. 
 
Compound Source 
1 4-methyl-7-hydroxycoumarin (4-methylumbelliferone) Extrasynthése (Genay, France) 
2 6,7-dimethoxycoumarin (scoparone) Extrasynthése (Genay, France) 
3 6-Hydroxy-7-methoxycoumarin (isoscopoletin) Extrasynthése (Genay, France) 
4 7,8-dihydroxy-6-methoxycoumarin (fraxetin) Extrasynthése (Genay, France) 
5 6,7-dimethoxy-8-hydroxycoumarin (fraxidin) Extrasynthése (Genay, France) 
6 7,8-dihydroxycoumarin (daphnetin) Extrasynthése (Genay, France) 
7 8-hydroxy-7-methoxycoumarin (7-methyetherdaphnetin) Extrasynthése (Genay, France) 
8 7-hydroxy-6-methoxycoumarin (scopoletin) Sigma–Aldrich (St. Louis, MO, USA) 
9 7- hydroxycoumarin (umbelliferone) Sigma–Aldrich (St. Louis, MO, USA) 
10 6-methylcoumarin (toncarine) Extrasynthése (Genay, France) 
11 4-hydroxycoumarin  Sigma–Aldrich (St. Louis, MO, USA) 
12 3-(1´-phenyl-2´-acetylehyl)-4-hydroxycoumarin (warfarin) Sigma–Aldrich (St. Louis, MO, USA) 
13 6-methoxy-4-methylcoumarin Extrasynthése (Genay, France) 
14 7-methoxy-4-methylcoumarin (4-methylherniarin) Extrasynthése (Genay, France) 
15 coumarin Sigma–Aldrich (St. Louis, MO, USA) 
16 5,7-dihydroxy-4-methylcoumarin Extrasynthése (Genay, France) 
17 6,7-dihydroxy-4-methylcoumarin (4-methylesculetin) Extrasynthése (Genay, France) 
18 7,8-dihydroxy-4-methylcoumarin (4-methydaphnetin) Extrasynthése (Genay, France) 
19 7-methoxycoumarin (herniarin) Carl Roth (Karlsruhe, Germany) 
20 6,7-dibromocoumarin-3-carboxylate Research Chemicals LTD (Lancs, 
UK) 
21 esculetin 6-?-D-glucoside (esculin) Sigma–Aldrich (St. Louis, MO, USA) 
22 6,7-dihydroxycoumarin (esculetin) Sigma–Aldrich (St. Louis, MO, USA) 
23 5-methoxypsoralen (bergapten) Carl Roth (Karlsruhe, Germany) 
24 8-methoxypsoralen (xanthotoxin) Extrasynthése (Genay, France) 
25 coumarin 153 AcrosOrganics (New Jersey, USA) 
26 coumarin 106 AcrosOrganics (New Jersey, USA) 
27 coumarin 102 AcrosOrganics (New Jersey, USA) 
28 coumarin 30 AcrosOrganics (New Jersey, USA) 
29 coumarin 7 AcrosOrganics (New Jersey, USA) 
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Figure 5. The structures of the screened coumarins in the coumarin library. 
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4.1.4 Synthetic Compound Library (IV) 
Compounds used during the screening campaign of the synthetic compound library 
belonged  to  the  commercial  libraries  of  ChemDiv  Inc  (San  Diego,  US),  ChemBridge  
Corporation (San Diego, US) and Tripos (St Louis, US). Altogether, 56,320 compounds 
were assayed for AChE inhibitory effect. 
4.2 Enzymatic Methods 
4.2.1 Ellman’s Reagent Based Photometric Microplate Assay (II, III, IV, V) 
Ellman et al. (1961) developed an assay for measuring AChE activity in a photometric 
assay using cuvettes and micro-cells. They applied it to isolated enzymes, blood samples 
and other tissues. In this assay, acetylthiocholine is used as a substrate. The hydrolyzed 
product, thiocholine, further reacts with dithionitrobenzoate (also called Ellman’s reagent) 
to form a yellow anion detectable at 412 nm. This assay has further been applied for BChE 
with butyrylthiocholine being the substrate. Ellman et al. (1961) utilized 
butyrylthiocholine as a substrate to compare several tissues for non-specific esterase 
activity. 
 
We used the AChE inhibitory assay in 96-well (II, III) and 384-well plate format (IV, 
V). HPLC micro-fractionated extracts (II), and pure compounds (III) were assayed in a 96-
well plate. For screening of the large synthetic chemical library in an automated 
environment, the AChE inhibitory assay needed to be miniaturized and validated for a 
384-well plate format (IV). 
 
The  BChE inhibitory  assay  was  used  in  a  96-well  plate  format  (III,  IV).  Hits  in  the  
large synthetic chemical library screening for AChE inhibition were assayed also against 
BChE. 
 
Ellman’s method is the most applied method for detecting acetylcholinesterase activity 
(e.g., Ingkaninan et al. 2000, Di Giovanni et al. 2008). Several modifications of the assay 
has been introduced which vary in substrate concentration, reagent concentration, enzyme 
source, enzyme concentration, detection wavelength, detection time, incubation time, 
incubation temperature and so on (e.g., Munoz-Ruiz et al. 2005a, Adsersen et al. 2007, 
Lee et al. 2007, Vinutha et al. 2007, Jang et al. 2008, Pan et al. 2008, Pereira et al. 2009, 
Tang et al. 2009). We compared different assay variants to see how the change in pipeting 
order and substrate concentration affects the potency evaluation (V). 
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Screening window coefficient (??-factor), signal to background ratio (S/B) (Zhang et 
al. 1999) and  signal  to  noise  ratio  (S/N)  (Bollini  et  al.  2002) were used to evaluate the 
quality of the assay performance (II, III, IV): 
 
?? = 1 ? [(3×SDs + 3×SDb)/|Xs ? Xb|] 
 
S/B = Xs/Xb 
  
S/N = (Xs ? Xb)/(SDs2 + SDb2)1/2 
 
Xs and  SDs = average and standard deviation of the maximum signal i.e. absorption 
detected at the last measurement point in blank wells after initiation of the reaction, Xb and 
SDb = average and standard deviation of the background i.e. the absorption at the first 
measurement point in blank wells after initiating the reaction. These parameters were 
utilized in the assay validation process and also as acceptance criteria to monitor changes 
in assay performance during the screening campaigns. 
4.2.2 Bioautographical Assay on TLC (I, II, III) 
Bioautography is a technique to couple a biological assay to TLC (Potterat and Hamburger 
2006). The developed TLC plate is sprayed with an enzyme solution. After an incubation 
period, the substrate and reagent are applied to the plate and inhibition zones are detected. 
The same technique is applicable also for detection of anti-microbial compounds where a 
developed TLC plate is dipped into a microbial suspension, and incubated after which 
microbial growth can be detected. 
 
For screening of AChE and BChE inhibitors the method developed by Marston et al. 
(2002) was followed. Briefly, cholinesterases catalyze the hydrolysis of 1-naphthyl acetate 
(substrate)  after  which  the  degradation  product  reacts  with  Fast  Blue  Salt  B  to  form  a  
purple azo dye. Inhibitors are detected as white spots against a purple background. The 
assay can be utilized to screen both acetylcholinesterase and butyrylcholinesterase 
inhibitors. Detection limits for the known AChE inhibitors physostigmine and galantamine 
as  well  as  for  the  fungal  compound  isolated  from  the  extract  of  Piptoporus betulinus 
(Bull.: Fr.) P.Karst were calculated from the densitograms created using VideoScan 
software (Camag, Muttenz, Switzerland). Usually evaluation of the detection limit has 
been done visually as the lowest detectable inhibitory band. 
 
This bioautographic assay was utilized for primary screening of fungal extracts (I), 
plant extracts (II), and coumarins (III) for AChE and BChE inhibition. 
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4.3 Separation and Analytical Methods 
4.3.1 HPLC Micro-Fractionation of the Extracts (II) 
An automated fraction collector (Gilson FC 204, Middleton, WI, USA) coupled with 
HPLC  equipment  (Perkin  Elmer,  Norwalk,  CT,  USA)  was  used  to  separate  and  collect  
compounds from extract directly into 96-well plates (Nunc, Roskilde, Denmark) with a 
collection time of 0.3 min/well (II). HPLC separation was achieved using a Supelcosil™ 
LC-18 column (250×4.6 mm, 5 ?m, Supelco, Bellefonte, PA, USA). The mobile phase, 
consisting of acetonitrile (ACN) (B) and water, was used at a flow rate of 1 ml/min. The 
gradient profile applied was: 0–30 min linear gradient from 5% to 95% B and 30–50 min 
isocratic 95% B. Injection volume was 20 ?l, sample concentration 10 mg/ml and 
detection wavelength 255 nm. The positive control for the acetylcholinesterase assay, 
physostigmine in MeOH (0.5 ?g/well, n = 12), was added to the plate and the solvents 
were lyophilized (HETO LyoPro 3000, Heto-Holten A/S, Denmark). For identification the 
compounds were collected from the plate before lyophilisation. 
4.3.2 TLC (I, II, III) 
TLC plates (DC-Alufolien Kieselgel 60 F254 Silica, Merck) were eluted first with acetone 
in order to wash them. The separation was carried out using CHCl3: MeOH: 2.5% acetic 
acid (aq) (65:35:5) (I, II, III) or CHCl3: MeOH: 0.1% acetic acid (aq) (65:35:5) (I) as an 
eluent. 
4.3.3 LC-MS (I, II) 
I) The HPLC-DAD-ESI-HRMS instrument (HRMS, high-resolution mass spectroscopy) 
used was an Agilent 1200 HPLC-system (Agilent Technologies, Waldbronn, Germany) 
connected to a Bruker micrOTOF-Q instrument (Bruker Daltonics, Bremen, Germany). 
The column used was a LiChrocart Purospher RP-18 (250×4.0 mm, 5 ?m, Merck, 
Darmstadt, Germany). The mobile phases in the HPLC gradient consisted of 10 mM 
NH4COOH in water and MeOH. The flow rate 0.7 ml/min was split 1:4 (0.14 ml/min to 
the MS instrument). The UV/VIS DAD data was recorded with an Agilent G1315C 
Starlight instrument (Agilent Technologies) in the wavelength range 190?950 nm. 
Negative ionization mode was used. 
 
II) The samples were separated first with an Agilent 1100 Series LC equipped with a 
diode array detector and directly connected to MS detector (Agilent MSD Trap XCT Plus 
mass spectrometer). A Zorbax SB-C18 column (50×2.1 mm, 3.5 ?m, Agilent 
Technologies, CA, USA) was used and eluted with ACN and water at a flow rate of 0.3 
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ml/min. 0.1% formic acid in ACN was added to the eluent before ionization at a flow rate 
of 0.05 ml/min. Electrospray ionization (ESI) was performed in positive ion mode. 
4.3.4 NMR (I) 
NMR spectra were acquired using a Bruker Avance 500 spectrometer (equipped with 
BBO-5mm-Zgrad probe) operating at 500.13 MHz for 1H and 125.77 MHz for 13C. 
Spectra were recorded at 25?C using methanol-d4 as a solvent. Proton and carbon spectra 
were referenced internally to tetramethylsilane (TMS) signal using value 0.00 ppm. 
 
1H and 13C proton-decoupled NMR spectra were acquired with single-pulse excitation 
and  30°  flip  angle.  Number  of  scans  for  carbon  spectrum was  21200.  Gradient  selected  
1H-13C HSQC spectrum was acquired with hsqcetgpsisp.2 pulse program using shaped 
pulses (pulse programs refer to original ones installed by Bruker) with 34 scans. Gradient 
selected 1H-13C HMBC spectrum was acquired with hmbcgplpndqf pulse program with 
260 scans. 
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5 Results and Discussion 
5.1 Ellman’s Reagent Based Photometrical Microplate Assay 
Ellman’s photometric assay to measure AChE activity was utilized in both 96-well plate 
(II, III) and 384-well plate formats (IV, V) in this contribution. The assay is applicable in 
miniaturized form for large scale high-throughput screening purposes for pure compounds 
but it is also a suitable platform for fractionated and crude extracts in 96-well plates. 
Possibility to modify the assay is an advantage in assay adaptation to different screening 
platforms but at the same time several modifications make comparison of the results in the 
literature close to impossible. The modifications in the assay variables are evaluated and 
discussed. 
5.1.1 Adaptation of the Assay for Screening of AChE Inhibitors 
The assay performance was validated and monitored using the statistical parameters Z’, 
S/N and S/B (Zhang et al. 1999, Bollini et al. 2002). The same parameters were utilized 
during screening with acceptance limits of Z’ ? 0.5, S/N ? 10 and S/B ? 4 (II, III, IV). The 
limits  were  set  to  ensure  robustness  and  reproducibility  of  the  assay  as  well  as  reliable  
identification of true hits. If conditions changed during screening for any reason it could 
be detected as a decrease in the values. Such changes could be technical, chemical or 
biological, e.g., due to incorrect pipeting volumes, errors in plate reading or mistakes in 
the concentrations of assay reagents. The screening window coefficient (Z’) and signal-to-
noise  value  (S/N)  are  more  reliable  indicators  of  assay  conditions  than  S/B  because  the  
values are affected if  variation increases between individual  wells  but  also if  the error is  
more systematic and occurs on the whole plate. Drift in side wells of a microplate would 
be detected if assay design was such that control wells were located on both side wells and 
middle wells. In the large screening campaign of a chemical library two columns on each 
side of a 384 plate were left for solvent controls and positive control, in this case DMSO 
(in 23 and 24 columns) and a known AChE inhibitor physostigmine (in 1 and 2 columns) 
(IV). 
 
The selected variables – mostly measurement time, reaction order and substrate 
concentration – were evaluated in this contribution. The effect of measurement time on 
assay reliability was evaluated by means of statistical parameters (Table 2). According to 
the set acceptance limits for Z’, S/B and S/N, the assay was reliable five minutes after 
starting the reaction if the reaction was initiated with the enzyme (at ATCI concentration 
1.5 mM). In the literature, measurement times are often shorter than that: e.g. 2 minutes 
(Chattipakorn et al. 2007, Langjae et al. 2007) or 1.7 minutes (Adsersen et al. 2007) 
(Appendix 1). The question is: can their modification of the method discriminate 
background variation from the signal? The authors have not discussed this issue in their 
publications. Short measurement times reflect to low S/B values. The Z’ value is directly 
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linked to S/B and the coefficient of variance (CV) (Sui and Wu 2007). Subsequently, in 
case of a low S/B value, a low CV is required for acceptable assay performance. A 
measurement time shorter than 2 minutes may be acceptable but great attention should be 
paid to the deviation. In our contributions, we used 8 minutes as the measurement interval 
to ensure good separation between the background noise and the signal. From a practical 
point of view, this measurement interval allowed reading of the whole 96- and 384-well 
plates at a time and dispensing of the solution that initiated the reaction using the 
microplate reader which was important for the kinetic measurements. 
 
 
Table 2. The effect of measurement time on statistical parameters Z’, S/B and S/N in a 96-well 
plate format. Assay conditions: reaction initiated with AChE (Reaction order 1), ATCI 1.5 mM, n 
= 94. Grey area represents values that would be accepted according to the acceptance limits: Z’ ? 
0.5, S/N ? 10 and S/B ? 4. 
 
Measurement 
time (min) 
Average 
change in 
absorbance sd CV  Z' S/B S/N 
1 0.35 0.03 0.081  -0.02 1.61 4.03 
2 0.48 0.04 0.076  0.39 2.22 6.57 
3 0.62 0.04 0.068  0.55 2.83 8.75 
4 0.75 0.05 0.067  0.62 3.46 10.08 
5 0.89 0.06 0.063  0.67 4.09 11.45 
6 1.03 0.06 0.056  0.72 4.70 13.50 
7 1.15 0.05 0.046  0.77 5.29 16.30 
8 1.28 0.05 0.042  0.80 5.87 18.96 
9 1.40 0.05 0.038  0.82 6.43 21.01 
 
 
 
When conducting the Ellman’s reagent based assay, the enzymatic reaction can be 
initiated either with the enzyme (AChE, reaction order 1) or the substrate (ATCI, reaction 
order 2). Both variants of the assay have been largely applied in the literature without 
further evaluation of the effect on results, e.g., reaction order 1 (e.g., Ingkaninan et al. 
2000, Adsersen et al. 2007, Chattipakorn et al. 2007, Rhee et al. 2003, Papandreou et al. 
2009) and reaction order 2 (e.g., Kwon et al. 2007, Zhu et al. 2009, Atta-ur-Rahman et al. 
2001, Liston et al. 2004, Pietsch and Gutschow 2005, Girisha et al. 2009). We evaluated 
these variants in more detail to confirm good assay performance and reliable detection of 
true hits in screening (Fig. 6, Table 3, Fig. 1 in IV and Table 1 in IV). 
 
Both reaction orders were validatable for screening (Table 3). Some differences were 
found that favoured the reaction order 2. The reaction order 2 had a wider signal window 
than reaction order 1. This is largely due to the spontaneous non-enzymatic hydrolysis of 
the substrate before initiating of the enzymatic reaction (Ellman et al. 1961) which 
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increases variation and background value if substrate solution and reagent solution are 
mixed before the enzyme is added (Fig. 6, Table 3). 
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Figure 6. The effect of reaction order on spontaneous hydrolysis in a 384-well plate format. The 
first two measurement points are background measurements. The reaction was initiated just before 
the third measurement point either with AChE (reaction order 1) or ATCI (reaction order 2). The 
kinetic interval was 8 minutes. The values are means and standard deviations (n = 72) (Table 3). 
A) Reaction order 1: Spontaneous hydrolysis of substrate without enzymatic catalysis increase the 
measured background values but also variation if the substrate solution is mixed with the Ellman’s 
reagent before addition of the enzyme. Standard deviation was up to 18.9%. B) Reaction order 2: 
The assay was robust using reaction order 2 because the standard deviation was less than 3% for 
all measurement points. 
 
 
 
With a 1.5 mM substrate concentration, the change in absorbance and accordingly the 
signal window, is greater than with a substrate concentration of 0.13 mM which can be 
seen  as  an  increase  in  Z’  values  in  both  variants  (Table  3).  Z’  values  for  a  substrate  
concentration of 0.13 mM are also above 0.5 which is considered as the limit for an 
excellent assay (Zhang et al. 1999). Nevertheless, percentual deviations for reaction order 
1 and reaction order 2 at this substrate concentration (13.5 and 11.10%, respectively) are 
significantly higher than with the substrate concentration 1.5 mM (4.60 and 1.66%, 
respectively). If the signal window is narrow the assay becomes sensitive to deviation 
which can lead to high rejection rates of plates in a screening campaign. 
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Table 3. The effect of reaction order on signal window coefficient (Z’) and measurements at 
several measurement points in a 384-well plate format. Reaction order 1: the reaction is initiated 
with the enzyme (AChE). Reaction order 2: the reaction is initiated with the substrate (ATCI). n = 
72. 
 
     Measurement point 
   Z'  b1 b2 s1 s2 
Reaction order 1  average  0.81  1.05 1.12 1.23 2.13 
(ATCI 1.5 mM) sd  0.04  0.20 0.20 0.21 0.17 
 CV  0.046  0.189 0.179 0.170 0.078 
         
Reaction order 1  average  0.60  0.87 0.91 0.99 1.23 
(ATCI 0.13 mM) sd  0.08  0.12 0.11 0.11 0.08 
 CV  0.135  0.133 0.125 0.115 0.064 
         
Reaction order 2  average  0.89  0.46 0.46 0.52 1.57 
(ATCI 1.5 mM) sd  0.01  0.01 0.01 0.01 0.04 
 CV  0.017  0.022 0.018 0.013 0.023 
         
Reaction order 2  average  0.71  0.46 0.47 0.55 0.92 
(ATCI 0.13 mM) sd  0.08  0.01 0.01 0.02 0.01 
 CV  0.111  0.029 0.023 0.039 0.015 
         
Z': signal window coefficient        
         
b1: change in absorbance at the 1st background measurement point 
b2: change in absorbance at the 2nd background measurement point 
s1: change in absorbance at the 1st signal measurement point 
s2: change in absorbance at the 2nd signal measurement point 
 
 
 
5.1.2 Effect of Assay Variant on Potency of Inhibition 
Assay modification was found to affect the potency evaluation of inhibitors with different 
kinetic properties and inhibitory mechanisms (Table 4, Fig. 1 in V). The structures of the 
studied compounds are presented in Fig. 7. When initiating the reaction with the substrate 
(reaction order 2), inhibitors are pre-incubated with the enzyme during the background 
measurements which is not the case with the reaction order 1. Therefore, reaction order 2 
favours the binding of slow-binding inhibitors, which is detected as an increase in their 
potencies. In practice, pre-incubation means that the screened compound is in contact with 
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the enzyme before the substrate is added. Physostigmine forms a complex with AChE 
slowly even though its Ki value (Ki, dissociation constant for an inhibitor for binding to 
the enzyme) is small (Stojan and Zorko 1997). It has been defined as slow reversible or 
pseudo-irreversible inhibitor because it forms a carbamylated complex with the serine 
residue in the catalytic triad of AChE which is hydrolyzed slowly thus, pre-incubation 
increases its potency (Camps and Munoz-Torrero 2002, Darvesh et al. 2003b, 
Augustinsson and Nachmansohn 1949, Darvesh et al. 2008). Accordingly, the IC50 value 
for physostigmine decreased when the reaction order was changed from order 1 to order 2 
at substrate concentration of 1.5 mM by 91-fold and at a substrate concentration of 0.13 
mM by 21-fold (Table 4, Fig. 1 in V). Sugimoto et al. (1990) observed even more 
substantial change (decrease in IC50 nearly 500-fold) with 60 minutes pre-incubation time 
when utilizing mouse brain homogenate as the enzyme source with a substrate 
concentration of 0.5 mM. In addition, competitive inhibitors, such as physostigmine, bind 
to the same site as the substrate (the catalytic site) and therefore increasing the substrate 
concentration increases the IC50 value without pre-incubation. This lowering of 
physostigmine’s potency was detected at the higher substrate concentration when reaction 
order 1 was applied. 
 
 
Table 4. IC50 values (?M) for the three AChE inhibitors (tacrine, physostigmine and E017-0008) 
using two assay variants and two substrate concentrations. The reaction was initiated either with 
the enzyme (AChE) or the substrate (ATCI). The effect of substrate concentration was assessed 
using concentrations of 0.13 mM and 1.5 mM. The values are averages ± standard deviations of 
three independent assays. For each compound, statistical comparisons of the potencies were made 
using one-way ANOVA and Tukey post test: statistical difference between the two substrate 
concentrations (a) and between the two reaction orders (b) (p < 0.05). The change in assay 
conditions did not affect IC50 of tacrine. Both changes – the substrate concentration and the 
reaction order – affected IC50 of physostigmine, whereas only the substrate concentration affected 
IC50 of E017-0008. 
 
  Reaction initiated with: 
 
ATCI 
concentration 
(mM) AChE (IC50, µM) ATCI (IC50, µM) 
    Tacrine 0.13 0.063 ± 0.013  0.065 ± 0 021  
 1.50 0.071 ± 0.008  0.071 ± 0.003  
    
Physostigmine 0.13 0.581 ± 0.060 a, b 0.025 ± 0.002 b 
 1.50 1.809 ± 0.175 a, b 0.020 ± 0.0005 b 
    
E017-0008 0.13 0.013 ± 0.004 a 0.008 ± 0.002 a 
 1.50 0.022 ± 0.0008 a 0.021 ± 0.001 a 
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Figure 7. The structures of the AChE inhibitors used for potency assessments. 
 
 
 
Potency  of  tacrine  (Table  4,  Fig.  1  in V) did not significantly change with the two 
substrate concentrations or the order of reagent addition which is in agreement with 
tacrine’s kinetic mechanism of a reversible mixed-type inhibitor with a strong non-
competitive component, i.e. the inhibitor binds with equal affinity to the free enzyme and 
enzyme-substrate complex (Berman and Leonard 1992). Nochi et al. (1995) and Pietsch et 
al. (2009) have determined ?? values for tacrine to be 1.1 and 1.4, respectively. ?? is  a  
factor which indicates how one ligand affects another ligand’s binding affinity. An ?? 
value = 1 indicates to a pure non-competitive mode of action. For a non-competitive 
inhibitor, the IC50 is independent of the substrate concentration and corresponds to the Ki 
(Macarron and Hertzberg 2009). Tacrine is not regarded as a slow-binding inhibitor thus 
pre-incubation with the enzyme does not affect tacrine’s inhibitory effect (Al-Jafari 1996, 
Ogura et al. 2000). Accordingly, the reaction order did not affect the potency of tacrine. 
 
One of the hits in the large screening campaign (E017-0008, ChemDiv Inc, San Diego, 
US)  was  further  investigated  with  both  reaction  orders  to  see  if  a  similar  pattern  of  
inhibitory behaviour to physostigmine or tacrine could be detected (Table 4, Fig. 1 in V). 
The reaction order had no effect upon potency but a statistically significant difference was 
detected between substrate concentrations. This behaviour indicates to a reversible 
competitive inhibitor but most probably with mixed mode of inhibition. It would require 
more detailed study to make any further conclusions. 
 
Knowing how substrate concentrations and the order of initiating the reaction affect 
the potency determination of AChE inhibitors allows the exercising of better judgement 
when selecting the optimal assay for large primary screening campaigns. In terms of 
substrate concentration, if the selected [S]/Km ([S], substrate concentration; Km, Michaelis 
constant, the substrate concentration at which the enzymatic reaction rate is half of the 
maximum velocity (Vmax)) ratio is lower than 1 the assay becomes more sensitive to 
competitive inhibitors, reaching an asymptotic limit in which IC50 would  be  equal  to  Ki 
(Cheng and Prusoff 1973). On the other hand, increasing the [S]/Km ratio makes the assay 
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more sensitive to uncompetitive inhibitors, which do not bind to the free enzyme. Thus, 
for screening purposes, the rationale of keeping the [S]/Km ratio  close  to  1  would  be  to  
guarantee the sensitivity of the assay to all types of inhibitors. Often, however, substrate 
concentrations need to be increased to achieve appropriated assay performance. In that 
regard, a high [S]/Km ratio  (i.e.  up  to  10)  may be  necessary  to  improve  the  assay  signal  
window. On the other hand, it is apparent that slow-binding inhibitors would need pre-
incubation with the enzyme prior to the starting of the reaction to get comparable results 
with fast-binders, so to ensure as few false negative hits as possible. Thus, choosing to 
start the reaction with the substrate for large screening campaigns would favour the 
robustness  and  stability  of  the  assay,  while  providing  a  more  reliable  hit  rate  for  both  
slow- and fast- binding inhibitors. 
 
Several other modifications of the assay including differences in temperatures, pre-
incubation times, pHs and reagent concentrations are found in the literature (Appendix 1). 
In addition, the data were conducted with enzymes from human, invertebrate and 
mammalian sources, under different enzyme concentrations and not all the conditions 
were even mentioned, which makes comparison of the results in the literature close to 
impossible. The conditions for a certain screening campaign have to be validated to be 
able to discriminate hits from background noise. If the results are to be used for further in 
silico structure-activity determinations in combination with results from the literature 
careful consideration of the assay format should be paid to create comparable results. As 
an example a reversible competitive inhibitor of AChE, galantamine (Camps and Munoz-
Torrero 2002), have been reported to have IC50 value of 3.18 µM (Lee et al. 2007), 0.88 
µM (Papandreou et al. 2009) or 1.4 µM (Adsersen et al. 2007) when initiating the reaction 
with the enzyme and 0.55 µM (Tang et al. 2009, Wen et al. 2008) or 1.82 µM (Berkov et 
al. 2008) when initiating the reaction with the substrate. Changes in assay conditions 
affect half-inhibitory concentration of inhibitors with various modes of inhibition but not 
to the extent of pseudo-irreversible carbamates. 
 
Like physostigmine, rivastigmine belongs to carbamate family of inhibitors and has a 
pseudo-irreversible mode of inhibition on AChE (Darvesh et al. 2008, Groner et al. 2007) 
which at least partially explains the extensive variation in the reported IC50 values in the 
literature, e.g., 0.03 µM (Rizzo et al. 2008) and 1.535 µM (Bolognesi et al. 2004). Groner 
et al. (2007) addressed the question of comparing IC50 values for carbamates and pointed 
out that the relationship between structure and therapeutic efficacy correlates better to 
individual rate constants between inhibitor and enzyme than IC50 values. Nevertheless, 
structure-activity relationship studies of AChE inhibiting carbamates found in the 
literature are conducted by comparing IC50 values  (e.g.,  Bolognesi  et  al.  2004,  Yu et  al.  
2001, Sterling et al. 2002, Bartolucci et al. 2006, Takahashi et al. 2010a, Takahashi et al. 
2010b). In general, a time-dependent inhibition mode is considered disadvantageous in 
biochemical screenings (McGovern et al. 2002, Rishton 2003). This mode of action leads 
to false-positive hits that most probably act on several targets. They are classified as non-
lead-like compounds that should be assayed in biological assays and not in large scale 
biochemical assays. Many times the time-dependent activity is due to non-specific 
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interactions such as aggregation, covalent binding, or electrophilic protein-reaction. The 
mechanism by which small aggregating compounds inhibit enzymes non-specifically in 
aqueous solutions is by partial denaturation of the protein structure (Coan 2009). Rishton 
(2003, 2008) defined properties for a good lead-like binder to be: i) non-covalent binding 
with high affinity, ii) reversible, time-independent competitive binding and iii) tractability 
in structure-activity relationship of a series of structural analogues of the binder. 
 
In case of AChE inhibitors, ruling out the time-dependent carbamates would leave out 
an important group of true hits. Consequently, as their mode of inhibition differs from fast 
binding compounds, they should be dealt with separately when conducting structure-
activity relationship data. When an assay is designed to detect both fast and slow binding 
inhibitors, i.e., compounds are pre-incubated with the enzyme before initiation of the 
reaction, including all hits into the QSAR studies after determining IC50 values without 
further information on enzyme kinetics will most probably, decrease the predictive power 
of an in silico model. In other words, founding in silico predictions merely on IC50 values 
should be done cautiously and kinetic constants should be preferred if available. The time-
dependent mode of inhibition cannot be evaluated based on IC50 values if just one reaction 
order is used which also highlights the importance of secondary studies. 
 
When data are combined from several publications in the literature for in silico studies 
careful attention should be paid on the assay conditions because modifications of the same 
assay may produce a different order of activities for inhibitors with several modes of 
action. A poor correlation as determined from the Spearman’s correlation coefficient for 
the reaction order 2 and both substrate concentrations is proof of a significant difference in 
assay modifications (Table 5). When using reaction order 1 changing the substrate 
concentration did not change the order of activities determined as IC50 values which 
correspond as Spearman’s correlation coefficient = 1. The lowest correlation was detected 
between reaction order 1 and 2 with substrate concentration of 1.5 mM. If the order of 
potencies changed with the change in assay modifications it is obvious that the predictive 
power of the in silico model created using IC50 values determined with different 
modifications of the assay would be poor. 
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Table 5. Spearman’s correlation coefficients for order of activities (IC50) for tacrine, 
physostigmine and compound E017-0008, when comparing two reaction orders and two substrate 
concentrations. Correlation coefficient = 1 means that changes in variables does not change the 
order of activities for the three compounds i.e. when using reaction order 1 E017-0008 had the 
lowest IC50 with both substrate concentrations and so on. When using 1.5 mM substrate 
concentration and reaction order 1, E017-008 had the lowest IC50 value whereas with reaction 
order 2, physostigmine had the lowest IC50 value which reflects as a poor Spearman’s correlation 
coefficient (-0.5). 
 
  Xi Yi 
Spearman's 
correlation coefficient
Reaction order 1  ATCI 0.13 ATCI 1.5 1
Reaction order 2  ATCI 0.13 ATCI 1.5 0.5
ATCI 0.13  Reaction order 1 Reaction order 2 0.5
ATCI 1.5  Reaction order 1 Reaction order 2 -0.5
5.2 Bioautographical Assay on TLC 
5.2.1 Evaluation of TLC Bioautography for the Screening of AChE and BChE 
Inhibitors 
Bioautographical AChE and BChE inhibitory assays were successfully applied for the 
primary screening of fungal extracts (I) and Mentha extracts (II). The method is straight 
forward and relatively fast after the TLC separation of compounds within the extracts. 
TLC bioautography couples analytical separation with a bioactivity assay therefore it is a 
good method to study extracts. Different Mentha species and parts of Mentha plants were 
extracted and assayed separately (Table 1 in II).  The  separation  of  compounds  on  TLC  
before the enzymatic assay enables comparison of the active bands between species as 
well as between parts of plants. The assay is more sensitive than the Ellman’s reagent 
based 96-well plate assay (Rhee et al. 2001). The detection limit for galantamine in the 
Ellman’s reagent based assay for AChE in the 96-well plate format has been reported as 1 
µM which correlates to 250 pmol/well whereas the calculated detection limit on the TLC 
using  method  of  Marston  et  al.  (2002)  was  280  fold  lower  (Fig.  3  in I). High detection 
capacity is fundamental for the screening of extracts because selective detection of active 
principles among mixtures even at low concentrations ensures good screening efficiency. 
 
Most often in the TLC bioautography, the enzyme activity has been determined as a 
detection limit that is visually evaluated from the dilution series of concentration (e.g., 
Marston et al. 2002, Di Giovanni et al. 2008). As an example, linarin showed 
concentration dependent inhibitory effect for AChE with a detection limit of 16.8 pmol 
/band (II). No inhibitory effect for BChE was detected. The detection limit for linarin was 
evaluated visually. Dependency of the value on the selected concentrations makes this 
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visually detected value an estimate. Densitometric determination of enzyme inhibitory 
effect utilizing VideoScan software was developed to calculate detection limits more 
accurately for AChE and BChE inhibitors (I). With this method the detection limit is 
based on multiple concentration points. Logarithmic correlation of concentrations to 
inhibitory band intensities determined as an area of the peak in the densitogram was used 
to create a formula from which a more accurate value was calculated. 
 
VideoScan software uses images captured by a CCD-camera (charge coupled devise 
camera) and VideoStore software for creation of the densitograms. Image analysis is not 
as sensitive a method for quantitative TLC compared to the measured densitograms. For 
the evaluation of the intensity and size of the enzyme inhibitory band, this less sensitive 
method is more suitable because spraying of the enzyme, substrate and reagent solutions 
to the TLC-plate leads to an uneven background. VideoScan software enables the manual 
editing of the baseline which is critical for the detection of inhibitory bands against the 
uneven background colour. The same plates could be measured densitometrically before 
the solutions for the enzymatic reaction are sprayed, and quantitative measures could be 
used for dose-response determinations of known compounds. Efficacy evaluation of the 
inhibitors in the extract was not as straight forward because the compounds in the extracts 
were not known. 
 
Evaluation of the kinetic parameters has to be conducted in a photometric assay, either 
using the Ellman’s reagent based assay or Fast blue salt B assay in a micro-well plate 
format  (Di  Giovanni  et  al.  2008).  In  general,  it  is  advantageous  to  use  two  methods  to  
make sure that the shown activity is due to a real enzyme catalyzed reaction and not due to 
inhibition of the reaction between the hydrolyzed substrate and the reagent (Rhee et al. 
2003). Some aldehydes and amines have been shown to give false positive results in the 
Ellman’s reagent based assay on the TLC and in the 96-well plate. 
5.3 Coupling Cholinesterase Inhibitory Assays and Analytical 
Techniques for the Screening of Extracts 
5.3.1 Tracking of Bioactive Compounds in Extracts 
The biggest advantage of coupling separation techniques to a bioactivity assays is the 
information that helps to associate the detected bioactivity with a peak in a chromatogram. 
Traditionally, the active compounds in the extracts have been tracked with bioactivity 
guided fractionation processes. The loss of activity during the isolation and purification 
processes is possible, particularly, if the concentration of the active compound in the 
extract is low (Hamburger 2003). If the activity is lost during the long process and no 
analytical data are available it is impossible to go backwards in the process. Coupling of 
separation to bioactivity assay enables usage of several detection methods on-line or off-
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line which fastens the identification of interesting compounds in the extracts. Splitting of 
eluent after HPLC separation enables simultaneous detection of separated compounds in 
the extract using on-line UV detector as well as MS and NMR spectrometers (Potterat and 
Hamburger 2006). In addition, a part of the eluent is directed to a fraction collector. After 
assaying the fractions,  the activity data of the most  active factions is  combined with the 
analytical and spectroscopical data. Preliminary structural information on the active 
compounds is created during one run. 
 
The crude extracts are complex mixtures of tens or even hundreds of compounds. A 
large part of the compounds in any extract are most probably known. A part of the 
compounds within an extract are totally new whereas a compound may be identified from 
the certain species for the first time even if it is known in another species. Fast 
identification of known compounds should be achieved without laborious separation steps. 
Using  time  and  labour  for  the  isolation  of  a  compound  that  turns  out  to  be  a  known  
compound has traditionally been one of the pitfalls in natural product screening 
(Hamburger 2003). 
 
Even if a compound is known it still may be interesting because new activities may be 
found for known compounds. At best, the identification of the known compounds can be 
achieved without further isolation based on UV and MS detection methods and with the 
help of literature. This was the case in the identification of linarin in the Mentha extract 
(II). After HPLC separation and micro-fractionation of the Mentha arvensis flower extract, 
inhibitory effect was associated with one peak in the chromatogram which was identified 
as linarin in the following LC-MS-MS analysis conducted using the same separation 
conditions as in the fractionation. In addition, the compound was commercially purchased 
as a pure compound and the inhibitory effect was confirmed on the TLC. In addition, the 
fragmentation was confirmed in MS-MS experiments. 
 
When the activity has been tracked to a certain peak in the chromatogram and the 
separation system is robust, repeated runs with a fraction collection can be utilized for the 
isolation of the compound. Optimization of the separation method should be done 
carefully because a robust method can be utilized in both the fractionation of the extract at 
the analytical scale and the isolation of the active compound (Wennberg et al. 2004). 
Optimization of the separation can be improved with the help of computational programs 
like DryLab (Molnar Institute) to achieve baseline separation that allows the increasing of 
the concentration of the injected sample and/or the injection volume to affect the efficacy 
of the isolation. An optimized separation can be scaled-up to a semi-preparative or 
preparative system. 
 
Fractionation of the extract prior the bioactivity assay reduces the complexity of 
samples (Potterat and Hamburger 2006, Wagenaar 2008). The crude extracts are mixtures 
of tens of compounds which can mask each other’s activities whereas viscosity and 
colours can interfere with the detection process. Fractionation lowers the viscosity of 
samples which results in improved physical properties making liquid handling more 
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accurate, especially at the microlitre scale. In general, fractionation increases the quality of 
the extract library which in turn improves the possibility to detect activity in the extracts. 
 
In TLC bioautography, the activity is traced to a certain band in the separated extract. 
Further identification steps are often laborious especially if another separation system such 
as preparative HPLC needs to be optimized for isolation. To get past this step, the active 
compound in the Piptoporus betulinus extract was isolated directly from analytical TLC 
plates (I). Good separation of the compounds of the extract on TLC and high enough 
concentrations of the active compound in the extract enabled the isolation. Extraction of 
the compound from TLC was relative laborious because 100 plates were extracted to get 
12 mg of pure compound for MS and NMR analyses. TLC-MS interface equipment could 
have been attached directly to the MS but further isolation was required for NMR analysis. 
GC-MS analysis is another technique that may be used for the identification of compounds 
on the TLC. As an example, the compounds possessing AChE inhibitory effect in the 
extract were scratched off the TLC plate and extracted from the silica with MeOH (Berkov 
et al. 2008). Dissolved compounds were analysed by GC-MS and identified as 
galantamine derivatives. 
5.3.2 The Effect of Solvents on Fractionation and Enzyme Activity 
Coupling an enzymatic assay to analytical techniques requires, most of all, studies on the 
effects of solvents upon the enzyme activity. Analytical solvents are evaporated before 
proceeding on to the bioactivity assay but some traces of the solvents can still be present 
especially on the TLC-plate but also in the wells of the micro-well plate. AChE and BChE 
were found to be sensitive to low pHs which narrows down the selection of useable 
eluents in HPLC and TLC when coupling separation techniques to bioassays (I, II). 
Formic acid could not be used even at low concentrations in the HPLC elution because the 
decrease in enzymatic activity could be detected when fractions were assayed. Solvents 
were evaporated from the microplate before the enzymatic assay but traces of acid in the 
wells led to increased deviation between wells. Consequently, gradient eluent used in the 
separation and fractionation of compounds in Mentha extracts consisted of water (A) and 
acetonitrile (B) (II). In this case, the peak of the active component, linarin, was relatively 
sharp with minimum tailing which enabled fraction collection according to time (0.3 
min/well with flow rate of 1 ml/min). If peaks are wide and the compound disperses 
between several wells the concentration of the compound in each fraction decreases which 
may lead to difficulties in detecting bioactivity and correct hit identification. In this 
project, assaying the fractionations was a secondary method for identification of the active 
compound because it was already known based on the TLC bioautography that the Mentha 
arvensis flower extract contained a selective AChE inhibitor. Nevertheless, the same 
fractionation approach could be used to create a pre-fractionated extract library for 
primary screening purposes. 
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Gradient eluents consisting of e.g. 0.005% trifluoroacetic acid (TFA) (aq) (A) and 
0.005% TFA in MeOH (B) have been used in the generation of pre-fractionated natural 
product libraries (Wagenaar 2008). The library plates were used in screening of 
compounds for kinase and ion channel activities and no effects of the solvents on the 
assays were reported. Similarly, 0.05 % TFA (aq) (A) and ACN (B) in the gradient elution 
did not affect an antimicrobial or cytotoxicity assay (Lang et al. 2006). Usage of acids or 
low pH buffers in eluents often sharpens the peak shape of ionizable elutes which is 
advantageous for fractionation (Wagenaar 2008). If an eluent contains any acid, the effect 
on  the  target  should  always  be  assessed,  whether  the  target  is  an  isolated  enzyme  or  an  
intact cell. In an ideal situation, each fractionated compound would be in a separate well at 
a high enough concentration which may be achieved if peaks are sharp. In reality, the goal 
in natural product library generation for pre-fractionated extracts is 1-5 compounds per 
well which can be further analysed and separated after tracking down the bioactivity to a 
certain well (Eldridge et al. 2002). If the separation is compromised, a proper 
concentration can be assured by using preparative LC for fractionation (Wagenaar 2008). 
On the other hand, more fractions correlate to more data points in screening which 
increases the workload extensively if hundreds of extracts are to be screened. In large 
screens, rough fractionation at a rate of ten fractions per extract increases the throughput 
in screening. 
 
In the bioautagraphical assay for AChE and BChE on TLC, usage of acids in the eluent 
decreased the enzyme activity on the plate. Consequently, poor contrast of inhibitory 
bands against the coloured background was detected. Lowering the concentration of acetic 
acid in the eluent allowed its use (I, II). The total percentage of acetic acid in the eluent 
mixture which did not affect the detection of enzyme inhibitory bands on TLC was 0.1%. 
This percentage was not exceeded in the assays (I, II). 
5.4 Cholinesterase Inhibitors from In-House Libraries 
5.4.1 Fungal and Plant Extract Libraries 
Extract screens require special attention in assay set-ups because extracts are complex 
mixtures of compounds possibly with very different chemical structures. TLC 
bioautography was found to be a sensitive method with low detection limits for AChE and 
BChE inhibitors. Primary screening of fungal and Mentha extracts  on  TLC  resulted  in  
detection of a high number of inhibitory bands. In further analyses, two new 
cholinesterase inhibitors were identified (I, II). The active compound in Piptoporus 
betulinus extract  was  directly  isolated  from  TLC  plates  (I).  The  requirement  of  high  
compound amount for NMR resulted in identification of only one of the inhibitory 
compounds from fungal extracts. Isolation directly from the TLC plates was achieved 
because the inhibitory effect was associated to a large peak in the densitogram. 
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Consequently, the inhibitory effect was lower than hoped-for. Isolation of a minor peak 
would have been even more laborious but at the same time the potency of the compound 
might have been higher. It is likely that the isolated and identified compound, 2,5-
dihydroxy-?-oxo-benzeneacetic acid, was not the most potent cholinesterase inhibitor in 
the screened fungal extracts. 
 
Micro-fractionation of an extract into 96-well plate using HPLC leads to a set of low 
volume fractions that have a low number of compounds per fraction. Tracking the active 
principle in the Mentha arvensis extract was successfully executed after HPLC micro-
fractionation (II). Tracking of the active compound to one peak in the chromatogram 
requires small fractions which were achieved by collecting the compounds according to 
time (0.3 min/well). Detection limits for AChE and BChE inhibitors are higher in micro-
plates compared to TLC which limits the use of this approach. 
 
Different Mentha species as well as different parts of plants were extracted and 
analysed for AChE and BChE inhibitory effect separately (II). The same active band was 
detected in several samples but the concentration varied which was detected as varying 
intensities on TLC. The comparison of related species reveals that there are differences in 
production of secondary metabolites between species. Also, the active compound was 
produced in all parts of plant. If the compound would be isolated from a plant in larger 
scale the selection of species as well as the part of plant for harvesting and isolation could 
be optimized for high yield. Natural supply of the bioactive compounds could be achieved. 
5.4.1.1 2,5-Dihydroxy-?-oxo-benzeneacetic Acid Isolated from Piptoporus 
betulinus Extract 
The dual cholinesterase inhibitor identified from Piptoporus betulinus (Bull.: Fr.) P.Karst 
was 2,5-dihydroxy-?-oxo-benzeneacetic acid (Fig. 8) (I). Only few literature reports of 
this compound exist. Crowden et al. (1967) have isolated it from basidiomycete fungus 
Polyporus tumulosus (Cooke). The compound showed dose-dependent inhibitory effect 
for AChE and BChE on TLC (Fig. 3 in I). The related structure, hydroquinone, inhibits 
AChE with an IC50 of 89 µM (Wang et al. 2007). Its inhibitory effect was shown to be a 
true enzymatic effect because the compound did not inhibit the reaction between the 
substrate and the reagent in the assay for a false-positive effect. 
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Figure 8. The structure of 2,5-dihydroxy-?-oxo-benzeneacetic acid, an AChE and BChE inhibitor 
isolated from a wood-rotting fungus Piptoporus betulinus. 
 
 
 
Fungal extracts were rich sources of cholinesterase inhibitors because 115 of the 
assayed extracts showed an AChE inhibitory effect and 72 of the extracts showed a BChE 
inhibitory effect (I). Most of the detected inhibitory bands were selective for either of the 
enzymes but also 17 dual inhibitory bands were detected (Fig 1 in I  and  Table  2  in I). 
Comparison of the relative Rf values (Rf, retardation factor) of detected inhibitory bands in 
different extracts revealed that 2,5-dihydroxy-?-oxo-benzeneacetic acid is not a common 
secondary metabolite in the fungi. The inhibitory effect was moderate but the structure 
allows chemical modifications of the side chains that could be conducted to enhance 
efficacy against both AChE and BChE. The structure would be a good starting point for 
the creation of series of derivatives. 
5.4.1.2 Linarin from Mentha arvensis Extract 
Linarin (Fig. 9) identified from the M. arvensis flower extract inhibited AChE selectively 
because no BChE inhibition was detected on TLC (II). Linarin is a known natural 
compound isolated earlier from, e.g., Valeriana officinalis L. (Fernandez et al. 2004), 
Calamintha grandulosa (Req.) Benth (Marin et al. 2001), Foeniculum vulgare Mill. Var. 
vulgare (Parejo et al. 2004), Chrysanthemum zawadskii var. latilobum Kitamura 
(Compositae) (Singh et al. 2005) and Buddleia cordata HBK (Martinez-Vazquez et al. 
1996, Martinez-Vazquez et al. 1998). It has been connected to biological activities, i.e., 
sedative and sleep enhancing properties (Fernandez et al. 2004), anti-cancer effect on 
prostate carcinoma cells (Singh et al. 2005), anti-inflammatory and antipyretic activities 
(Martinez-Vazquez et al. 1996, Martinez-Vazquez et al. 1998). 
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Figure 9. The structure of linarin showing the annotation of flavonoid rings (A-C). 
 
 
 
Fan et al. (2008) studied 16 structurally related flavonoids to linarin and found that 
only tilianin is active against AChE in addition to linarin. The detection limit for tilianin 
for AChE on TLC is 90 pmol /band whereas the detection limit for linarin was 17 pmol 
/band (II). Tilianin’s structure is similar to linarin except it lacks the rhamnoside moiety. 
Interestingly, fortunellin which differ from linarin only by an inter-glycosidic linkage is 
not active. Together with our findings it can be stated that a methoxy group in position 4´ 
in the B-ring and a 7-O-sugar are essential structures for the observed AChE inhibitory 
effect. 
 
Pectolinarin acetates also inhibit AChE (Loizzo et al. 2008). Structurally, the 
pectolinarin aglycone has an additional methoxy group in position 6 in the A-ring 
compared to linarin. Pectolinarin acetates have an acetate group attached to the 
rhamnoside moiety through one of the OH groups at the position 2´´´´, 3´´´´  or 4´´´´. On the 
contrary, linarin acetate was not active (I). Linarin did not inhibit BChE (I) but some other 
flavonoids have been shown to have moderate BChE inhibitory effect such as quercetin 
with Ki of  3.8  ?M  (Khan  et  al.  2009)  and  galangin  with  Ki of 6.9 ?M (Katalinic et al. 
2010). 
 
The active band in the Mentha extracts  had  the  same  Rf value (0.81) but different 
intensities which indicated to one active compound with varying concentrations in the 
extracts (II). Intensive inhibitory bands were detected in all parts of the plants but there 
were differences between species. An intensive inhibitory band could be detected in five 
out  of  seven  flower  extracts  whereas  only  one  of  the  root  extracts  showed  the  same  
intensive band. The varying concentrations between the parts of the plant was expected 
but not between species at the extent detected. All parts of M. x gentiles showed the clear 
inhibitory band whereas only the flower extract of M. pulegium showed any detectable 
inhibitory effect. 
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5.4.2 Compound Libraries 
The pure compound libraries varied in size and origin (III, IV). Based on the literature, 
some of the coumarins were known to have cholinesterase inhibitory effects. 
Consequently, a selection of compounds having a coumarin scaffold to create a targeted 
coumarin library for screening of cholinesterase inhibitors was a straight forward strategy 
(III). Most of the compounds were of natural origin but also their synthetic derivatives 
were included in the library. Targeted libraries require low throughput in screening which 
leaves room for the assay selection and format. The hit rate for the coumarin library was 
17.2% for AChE inhibitory effects. The likelihood of finding hits in a targeted library 
screening is higher than in a randomly selected compound library because the selection of 
compounds into the library is based on a prior knowledge and a defined criterion. 
 
The random screen of a large library of synthetic compounds requires higher 
throughput in screening for which the Ellman’s reagent based assay was miniaturized for 
384-well  plates  and  validated  for  an  automated  environment  (IV).  Overall  hit  rate  was  
0.67% of the screened 56,320 compounds. Hit rates for the two screens are not totally 
comparable because of the differences in concentrations and hit limits. The comparison of 
the hit-rates gives a general idea of the power of a targeted compound selection over 
random selection. The concentration of compounds in the assay plates in the synthetic 
compounds screen was 2.5 ?M and hit limit 4 SDs from the average whereas in coumarin 
screen concentration was 5 ?M and hit limit 3 SDs from the average. The hit limit should 
be  strict  for  the  large  scale  screens  because  even  a  low  hit  rate  may  result  in  tens  or  
hundreds of hits. Hit rate as low as 0.67% resulted in 350 hits in the synthetic compound 
screen which led in a high number of data points in the secondary screening. In the large 
screening campaign, the compounds were transferred from the library plates to the assay 
plates using a pin-tool which is not as presice tool as a pipet. The pins are dipped into a 
solvent (DMSO) containing the compounds and then dipped into the assay buffer. The 
amount of the sample that is transferred from one well to another was assessed to be 0.14 
?l. The variation between wells was 7–10%. The pins are washed and re-used which 
makes it a cost-effective technique when thousands of compounds are screened. The 
variance in transfer was another reason why the hit limit was set 4 SDs from the average 
instead of 3 SDs. 
5.4.2.1 Hits in the Coumarin Library 
The coumarin library that contained natural coumarins and their synthetic derivatives was 
screened for AChE and BChE inhibitory activities (III). Synthetic coumarin derivatives 
were identified as hits at 5 ?M concentration against AChE with coumarin 106 being the 
most active one (compounds 25-29, Fig. 1 in III) (Fig. 10). The IC50 value for coumarin 
106 was 10.4 ?M and Ki 2.36 ± 0.17 ?M. The mode of AChE inhibition was of the mixed 
type. Coumarin 106 also inhibited BChE but with a slightly lower potency of IC50 27.8 
?M. A compound aimed to act in the CNS should have properties enabling the penetration 
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through the blood-brain-barrier (BBB). The potency in an in vitro experiment alone should 
not be overestimated because of the compounds pharmacokinetic properties may affect its 
activity in vivo substantially. Passive BBB transport can be predicted by calculating the 
logBB value for the compound (Vilar et al. 2010). The logBB for coumarin 106 is higher 
than 0.3 which is the limit for good passive penetration to the CNS, therefore the structure 
is favourable for passive BBB transport. In addition, the number of hydrogen acceptors (3) 
and donors (0), the clogP value (4.48) and the molecular mass (281.34 g/mol) of coumarin 
106 predict favourable oral absorption properties (Lipinski et al. 1997). 
 
 
O ON
 
 
Figure 10. The structure of coumarin 106. 
 
 
 
The coumarins’ inhibitory effect for AChE has been studied previously in many papers 
in the literature. Some of the natural coumarins inhibit AChE in the micromolar range but 
semi-synthetic coumarin derivatives are significantly more potent. Scopoletin has been 
shown to inhibit AChE in a dose-dependent manner with IC50 of 168 ?M (Rollinger et al. 
2004). The effect in vivo is comparable to galantamine although galantamine is much 
more potent in vitro. It is noteworthy that the 7-O-glucoside of scopoletin, scopolin, gave 
the highest response in vivo which can be considered surprising because the IC50 value in 
vitro is in the millimolar range. In our screening, at the concentration of 30 ?M, scopoletin 
showed inhibition just above the hit limit which is in agreement with the literature. 
Potency of scopoletin can be altered by chemical modification. A scopoletin derivative 
with a 3-{4-[(benzylethylamino)methyl]-phenyl} -substituent at position 3 has 
substantially lower IC50 value (18.3 nM) (Piazzi et al. 2008). 
 
Zhou et al. (2008) synthesized a series of coumarin derivatives to investigate the 
structure-activity relationships of the compounds for AChE. Substitutions in the positions 
3 and/or 4 of coumarin ring were shown to increase AChE inhibitory potency where as the 
substitution in the position 6 was not considered important for the interaction. The 4-
phenylpiperazine substituted coumarin compound has an IC50 of  4.5  ?M.  On  the  other  
hand, Pisani et al (2010) created a series of AChE inhibitors with different coumarin 
scaffolds attached to a edrophonium-like fragment and found that the 6,7-
dimethoxycoumarin scaffold with an edrophonium fragment attached to position 3  is the 
best scaffold for creating potent AChE inhibitors acting in the picomolar range. In our 
screening, 6,7-dimethoxycoumarin was just above the hit limit at a concentration of 30 
?M which indicates that the additional substitution is essential for increasing the potency. 
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In addition, coumarin has been a scaffold for creating dual inhibitors. Some of the dual 
inhibitors are designed to inhibit AChE’s active and peripheral sites (Piazzi et al. 2003, 
Shen et al. 2005) but dual inhibitors can be designed to inhibit two different enzymes like 
AChE  and  ?-secretase  (BASE)  (Piazzi  et  al.  2008)  or  AChE  and  monoamide  oxidase  
(MAO) (Brühlmann et al. 2001). These strategies aim to affect amyloid aggregation to 
create disease modifying therapies for AD. 
5.4.2.2 Hits in the Synthetic Compound Library 
Three of the hits in the synthetic compound library had potencies in the low nanomolar 
range (Table 6, compounds 1-3) (IV). The most potent hit ((N-[3-(3,5-dimethyl-1-
piperidinyl)propyl]-5-ethyl-2-methyl-8-oxo-thieno[2',3':4,5]pyrrolo[1,2-d][1,2,4] triazine-
7(8H)-acetamide)) had an IC50 value of 0.019 ?M. The second most potent hit turned out 
to be the known cholinesterase inhibitor tacrine which unexpectedly served as a reference 
for the screening. Altogether, 42 of the hits had IC50 value between 0.1 ?M and 1 ?M (Fig. 
11). 
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Figure 11. IC50 values of the hits for AChE in the synthetic compound library. The values were 
measured using the kinetic approach (grey bars). In comparison, the results were re-analysed as 
only the endpoint measurement was used (white bars). Altogether, 51 of the compounds in the 
category of 10 µM > IC50 > 1 µM would have been false negatives if only the end point 
measurement was used. Most of the hits had an IC50 in the micromolar range but the three best hits 
were in the nanomolar range. 
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Table 6. The  structures  and  IC50 values for the most potent hits in the screen of the synthetic 
compound library for AChE, as well as their IC50 values for BChE determined in the secondary 
phase of screening. 
 
  AChE IC50 (?M) BChE IC50 (?M) 
1 NS
O
N
N
O
NH N
 
0.019 13.270 
2 
                 N
NH2
 
0.063 0.0108 
3 
    
N
N
O
N
N
S
N
O  
0.069 23.580 
4 N
N
H
O
N
H
O
N
Cl
 
0.152 nd 
5 
     
O
N
H
O N
 
0.204 10.850 
6 
NS
N
N
N
HN
 
0.229 nd, x 
7 
       
N
NNN
H
N
N
F F  
0.236 nd 
8 NH
NO
Br
O
 
0.315 nd 
9 
N
N
H
O
O
NH
N
 
0.332 nd 
nd: IC50 not determined, BChE inhibition < 50% at concentration 3.3 ?M; x BChE inhibition 86.8 % at 3.3 
?M but IC50 not determined 
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In the large screening of the synthetic chemical library, the kinetic approach was 
utilized in both primary and secondary screening phases. The time consumed on this 
approach is undeniably long but if the results were re-analysed with only the endpoint 
being measured, 51 of the compounds in the category of 10 µM > IC50 > 1 µM would have 
been false negatives (Fig. 11). The most potent false negative would have been a 
compound displaying an IC50 of 1.35 µM. The most active compounds in categories IC50< 
1 µM would have been detected but if follow-up studies are considered among others in 
silico predictions a large set of data would have been miss-interpreted which can lead to 
low predictive values, e.g., in QSAR studies. The quality of the created dataset is essential 
if the results are to be used in follow-up studies. 
 
The primary screening phase was conducted as a single point analysis using one 
concentration of compound (IV). The analysis of the data was qualitative because all hits 
below the set hit limit (4xSD) were subjected to the secondary screening in which the 
dose-dependency was evaluated using eight concentrations. The single concentration 
analysis creates a possibility for false negatives in this phase. The primary screening can 
also be conducted as a quantitative multipoint analysis. Inglese et al. (2006) utilized 7 
concentration points in the primary screening for 60,000 compounds in a 1536-well plate 
format. They also analysed the data as if only one concentration point was used and 
realized that up to 75% false negative rate was possible when a 6xSD threshold was used 
for the detection limit. The false negative rate was 40% when a 3xSD threshold was the hit 
limit. Quantitative screening would always be preferable if appropriate liquid handling 
equipment is available and the assay set-up is miniaturizable to 1536-well plate format 
because the solvent consumption does not increase compared to a single point assay in a 
384-well plate format. The consumption of compound may even decrease. Instead, the 
number of plates and the number of data points increase which sets limits if the detection 
is the rate limiting step. Data created in quantitative screening is based on pharmacology 
whereas evaluation of data in qualitative single point screening is based on statistical 
analysis. The potency is often dependent on assay design which further highlights the 
importance of high data quality and favour quantitative over qualitative analysis. 
 
All  hits  in the AChE screening were subjected to a follow-up screening for BChE to 
investigate selectivity of inhibition. Compounds were primarily assayed at a single 
concentration of 3.3 ?M after which the compounds showing more than 50 % inhibition 
were subjected for IC50 determinations. Tacrine was more potent for BChE over AChE as 
would be expected but otherwise the eight most active AChE inhibitors were more potent 
for AChE over BChE (Table 6). 
 
Five of the hits in the AChE screening were found to inhibit BChE with substantially 
higher potencies (IC50 values against BChE were in the nanomolar range). The lowest 
detected IC50 against  BChE was 6.1 nM. The IC50 of  the same compound against  AChE 
was 1.78 µM which makes the compound highly selective for BChE over AChE. The 
active site of AChE is located in the bottom of the tight gorge whereas the active site of 
BChE is more accessible to compounds which could partly explain why some of the 
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moderate AChE inhibitors were more potent BChE inhibitors (Saxena et al. 1997). 
Selectivity is mostly based on interactions of a specific group or atom in the compound 
with a specific amino acid residue in the enzyme. The amino acids in the active sites of the 
two enzymes differ which makes size of the compound just one of the factors affecting the 
selectivity. 
 
The possible interactions of the most active compound in the screen for AChE and 
BChE were evaluated in in silico docking studies (IV). This hit apparently binds at the 
entrance of the gorge site of AChE, due to the ??? stacking interactions between thiophene 
and the pyrrole ring of the compound and the aromatic Trp279 in AChE (Fig. 4 in IV). 
This residue belongs to the PAS region of AChE and suggests the possibility that it could 
interfere with amyloid fibrillogenesis in addition to inhibition of the catalytic function of 
the enzyme. 
5.4.3 Chemical Evaluation of the Hits in the Libraries 
ChemGPS-NP is a model that maps compounds into a chemical space that is relevant to 
biology (Larsson et al. 2007, Rosén et al. 2009). The model has been created based on the 
compounds in the Dictionary of Natural Products which is comprised of 167,169 natural 
compounds. Later on, more than 1 million unique compounds have been complied for the 
subsequent validation of the model. Natural compounds occupy a larger and different 
space than compounds traditionally dealt with in medicinal chemistry. The fact that the 
model has been created using natural compounds makes it more predictive for biologically 
relevant chemical space than other chemical space models. The model uses all together 35 
descriptors. The dimensionality has been reduced using principal component analysis 
leading to eight principal components (PC) describing molecular properties in the final 
model. The first four PCs explain 77% of the variance. PC1 represents size and shape; 
PC2 represents aromaticity and conjugation-related properties; PC3 corresponds to 
lipophilicity, polarity, and H-bond capacity, whereas PC4 expresses flexibility and 
rigidity. The size increases in the positive direction of PC1; the degree of aromaticity 
increases in the positive direction of PC2; hydrophobic compounds are situated in the 
positive directions of PC3 and hydrophilic compounds in the negative direction of PC3; 
and compounds are increasingly flexible in the positive direction of PC4 and more rigid in 
the negative direction. The ChemGPS model for medicinal compounds or drug-like 
compounds differs from ChemGPS-NP model in the order of explained properties. In the 
ChemGPS model, lipophilicity descriptors are the second most important descriptors 
explaining the variance, whereas flexibility and rigidity parameters are the third most 
important descriptors. Medicinal compounds tend to be more lipophilic than natural 
compounds which explain the change in order of descriptors. Natural compounds are 
evolutionarily optimized to function optimally in hydrophilic environments, e.g., inside 
cells and solutions meant for defence. 
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The chemical properties of the hits in the extract libraries, linarin and 2,5-dihydroxy-?-
oxo-benzeneacetic acid, differed from each other in size, aromaticity and rigidity which 
can be seen clearly when comparing the PC1, PC2, and PC4 dimensions (Figs. 12 and 14). 
Nevertheless, the values describing lipophilicity (PC3) were close to each other, -2.00 and 
-2.32, respectively. Linarin is a diglycoside which makes it very different from any other 
compound mapped on the charts (Figs. 12-14). Size and aromaticity of 2,5-dihydroxy-?-
oxo-benzeneacetic acid mapped close to the region of natural coumarins which was seen 
in the PC1 to PC2 chart (natural coumarins have closed symbols without numbers in Fig. 
13). 
 
 
 
Figure 12. The hits identified from the natural extract libraries (linarin and 2,5-dihydroxy-?-oxo-
benzeneacetic acid), and known cholinesterase inhibitors (galantamine, donepezil, rivastigmine, 
physostigmine and tacrine) mapped into the biologically relevant chemical space using the 
ChemGPS-NP model (Larsson et al. 2007, Rosén et al. 2009). 
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Figure 13. Mapping of the hits in the synthetic compound library (open symbols), and all coumarins in the coumarin library (closed symbols), using the 
ChemGPS-NP model (Larsson et al. 2007, Rosén et al. 2009). The most active compounds in the synthetic compound library were C785-3659, tacrine, 
and E017-0008 (compounds 1-3 in Table 6). The synthetic coumarins are marked with numbers. (Fallarero et al., unpublished data) 
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Figure 14. Mapping of the three most active hits in the large synthetic compound screening 
(C785-3659, tacrine, and E017-0008), the hits in the extract libraries (linarin and 2,5-dihydroxy-?-
oxo-benzeneacetic acid), the synthetic coumarins (coumarin 106 and compounds 25, 27-29) as 
well as known cholinesterase inhibitors (galantamine, donepezil, rivastigmine, and physostigmine) 
using the ChemGPS-NP model. Each of the first three dimensions (PC1-3) was compared to 
rigidity (PC4). 
 
 
 
The synthetic hits occupied a large area on the PC1 to PC2 chart (Fig. 13). Even so, the 
coverage  of  chemical  space  was  limited  mostly  to  the  negative  range  of  PC1  and  the  
positive range of PC2. Most of the natural coumarins (closed symbols without numbers) 
were even at a lower region on the PC1 scale than synthetic compounds (Fig. 12). The 
synthetic compounds were mostly in the positive region on the lipophilicity scale (PC3) 
whereas all the natural compounds including the natural coumarins, linarin and 2,5-
dihydroxy-?-oxo-benzeneacetic acid were in the negative region on the PC3 scale. The 
finding supports the general view that synthetic compounds in HTS libraries are more 
lipophilic than natural compounds which was also noted by the authors when creating the 
ChemGPS-NP model (Larsson et al. 2007 and Rosén et al. 2009). It is worth keeping in 
mind that the synthetic compounds mapped on the charts (Figs. 13 and 14) were all hits in 
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the primary screening phase. General comparison between natural compounds vs. 
synthetic compounds based on these results may be biased. Nevertheless, it can be stated 
that the discovered synthetic AChE inhibitors, including synthetic coumarins, were more 
lipophilic than the two discovered natural AChE inhibitors. 
 
The ChemGPS-NP model has also been used to compare drugs and natural compounds 
(Rosén et al. 2009). It has been shown that some of the natural compounds that map close 
to a certain drug possess similar activities, e.g., against targets like angiotensin-converting 
enzyme, calcium channels blockers, and several viral enzymes. To some extent, chemical 
properties seem to correlate to activity. Consequently, the ChemGPS-NP model can be 
applied to find new active compounds or at least narrow down the number of compounds 
selected for screening. The known cholinesterase inhibitors, galantamine, donepezil, 
rivastigmine, physostigmine, and tacrine, were mapped on the charts with the new 
cholinesterase inhibitors to see if the active compounds would map with close proximity 
to each other (Figs. 12 and 14). Further detailed calculations need to be conducted before 
any final conclusions could be drawn. 
 
Some preliminary observations were made for cholinesterase inhibitors. The five 
known inhibitors mapped on the negative scale of PC1 and on the positive scale of PC2 
(Figs. 12-14). The values on the PC3 scale were close to zero except for donepezil which 
was 1.84. Similarly, most of the hits in the synthetic compound library and the synthetic 
coumarins which were above the hit limit at the concentration of 5 ?M mapped on the 
negative scale of PC1, to the positive scale of PC2, and to the scale of -0.5 –1.5 on PC3. In 
general, most of the active compounds were: i) rather small in size and shape, ii) they were 
highly aromatic, and iii) were to some extent lipophilic. Interestingly, none of these 
generalizations applied to linarin, whereas 2,5-dihydroxy-?-oxo-benzeneacetic acid was 
an outlier for lipophilicity. 
5.5 Production and Management of the Libraries for Screening 
5.5.1 Extract Libraries 
Natural products have been shown to contain a large variety of structurally diverse 
compounds (Lee and Schneider 2001, Newman 2008). Natural compounds are synthesized 
by biological organisms which means that the compounds are likely to interact with 
biological targets and they are “designed by evolution”. On the other hand, biological 
environment is a challenging producer which cannot be as much controlled as chemical 
synthesis. When natural extracts are included in libraries for screening, the supply of the 
extract has to be secured at least until the active compound has been identified. The same 
species do not produce the same compounds in all conditions and not even with the same 
conditions (Samuelsson and Bohlin 2009). Also, it is possible that cultures that are derived 
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from  the  same  cultivar  and  grow  in  the  same  incubator  next  to  each  other  vary  in  
secondary metabolite production. Several factors, partly unknown ones, affect this 
equation. 
 
Plant  or  fungal  material  may  be  isolated  from  the  nature,  may  be  grown  in  a  
greenhouse or on a field or may be grown in a culture. Each approach may be valid but 
may also create problems. The process of creating a natural compound library has to be 
well documented from the collection of the species, the identification of the species, to the 
handling and storage of the material (Samuelsson and Bohlin 2009). Samples from nature 
are identified by an expert on the specific field and collected in a herbarium which can be 
used for later verification if needed. Documentation reduces the effect of unknown factors. 
Mentha samples screened in this contribution for AChE and BChE inhibitory effects were 
extracts of different species and variants but also different parts of the plant (II). A part of 
dry plant  material  for  each sample was reduced in size and extracted to make an extract  
library which leaves an opportunity to go back to the extraction phase if more of the 
extract is needed later on. 
 
The fungi screened in this contribution belong to a large culture collection which is 
maintained at the Department of Food and Environmental Sciences, Faculty of Agriculture 
and Forestry, University of Helsinki. The samples are mainly collected from nature during 
years of research and identified by numerous experts. The cultures are maintained on agar 
plates. For screening, fungi were inoculated in liquid cultures, grown for eight weeks after 
which the liquor was extracted with ethyl acetate (I). In principle, it is possible to grow 
more cultures if the supply of the extract runs out. In practice, during the growth period 
which is relatively long due to the slow growth rate of the polypore fungi, there is a risk 
that not the same secondary metabolites are produced in the repeated cultures. At least, the 
concentrations and rates of the metabolite may vary. To minimize this effect, three parallel 
cultures were grown at the same time and the liquors were pooled before extraction. 
 
To avoid re-culturing the material, the use of increased sizes of the initial culture to 
create two parallel sets of the extract is wise: a working batch for fractionation and crude 
extract screening and a freezed batch as a back-up may be considered (Wagenaar 2008). 
The back-up crude extract can be utilized for isolation and identification or the compound. 
There is a possibility that the organism does not produce the same metabolites if it is 
cultured again. Even if the same metabolites would be produced much time is saved if 
repeating the growth period and chemical and biological analyses are avoided. 
5.5.2 Compound Libraries 
The compounds in the synthetic compound libraries are designed to be drug-like according 
to the rule of five (Lipinski et al. 1997). Several rules have been defined for compounds in 
HTS chemical libraries which aim to exclude non-lead-like chemical structures that 
contain reactive functional groups which potentially bind covalently to proteins from 
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libraries (Rishton 2008, Baell and Holloway 2010). Lead-likeness can be achieved by 
designing the chemical library in the way that it discriminates structures that are likely to 
produce false-positive results in large scale biochemical screens (Baell and Holloway 
2010). The following rules are designed for this goal: i) molecular weight 200–350, ii) 
clogP < 3, iii) single charge present, iiii) exclusion of chemically reactive functional 
groups, promiscuous inhibitors, frequent hitters, and “warheads” like covalent binders and 
iiiii) exclude peptides (Rishton 2008). As a result, the discrimination of structures 
decreases the structural diversity of the library but also decreases the workload in the 
following phase of the drug discovery pipeline because lead-like compounds should 
“behave properly” in, e.g., in silico models. 
 
In addition, certain structural elements are more likely to lead to coloured or 
fluorescent compounds that interfere with assays and should therefore be eliminated from 
chemical libraries as non-lead-like structures (Baell and Holloway 2010). Assay 
development and validation are essential steps to decrease the possibility of assay 
interference. Assay designs aiming to detect effects of real target-ligand interactions 
increase the rate of true hits. Addition of a nonionic detergent to an enzyme assay prevents 
nonspecific inhibition by aggregating compounds (Ryan et al. 2003) or the use of time-
resolved fluorescent detection to decrease the effect of compound fluorescent (Thorne et 
al. 2010) are examples of the matters that can be addressed in the assay design phase. 
 
False negatives and positives create a real problem for screening and data applicability 
for which different means have been used to minimize this effect. Posner et al. (2009) 
introduced a method to enhance hit selection via a local hit rate analysis. This method 
evaluates true hits in screening by comparing a compound’s activity to the activity of their 
structural analogs. The probability of finding a true hit increases if the analogs also show 
activity. This approach can be applied for selection of hits for secondary screening and 
also for the finding of false negatives. 
 
The management of the good quality of pure compound libraries is essential for 
screening. The quality of the library, determined as high purity of the compounds, correct 
identity of compounds and implementation of information technologies in compound 
management, reflects directly to the quality of the data created (Houston et al. 2008). The 
flexible format of the compound deck allows adding of new compounds into it, adding of 
structural and biological information about the compound into the databases and managing 
the inventory of the existing samples. The inventory includes compound stability and 
integrity studies of the dissolved library samples (Janzen and Popa-Burke 2009). In the 
early days of HTS when compounds produced by combinatorial chemistry were included 
in the screens for the first time, the purity of the samples was low. Nowadays, the integrity 
of the samples included in the libraries is prioritised because it is acknowledged that 
chemical errors decrease the quality of data which leads, e.g., to errors in SAR analyses. 
 
The storage and handling of dissolved samples, usually in DMSO, over long periods of 
time is a risk for compound integrity (Matson et al. 2009). Storage of the plates in low 
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temperatures and therefore repetitive freezing and thawing cycles of the plates for each 
screen may lead to degradation of compounds. Some compounds are more susceptible for 
the temperature changes than others. Also, DMSO is a solvent that absorbs water easily 
which is more profound during freezing and thawing (Janzen and Popa-Burke 2009). 
Increase in water content changes the physicochemical properties of DMSO, including 
solvation properties. There are different practices between the pharmaceutical companies 
to store the compounds. In any case, the best practice to evaluate structural integrity is to 
include analytical methods to the screening process and the library inventory. 
5.6 Selection of Compounds in a Library for Screening 
The implementation of a prior knowledge and information technologies in the screening 
are shifting the HTS screens from completely random to more focused direction which 
should be seen in the future as a maximized chances for success. Natural and synthetic 
compounds should both be implemented in screening platforms to increase the efficacy in 
finding good hits and future clinical candidates. As proven in the screens of this 
contribution, both natural sources and a commercial synthetic compound library were 
shown to contain compounds able to inhibit cholinesterases with various selectivities and 
potencies. 
 
Including natural pure compounds in chemical decks is a possibility for screening 
facilities to increase the diversity of compound structures in libraries if they do not want to 
handle extracts (Drewry and Macarron 2010, Sukuru et al. 2009). If structure diversity is a 
selection criterion for a certain screen in the industrial set-ups, a large fraction of natural 
products is usually selected because of their inherent chemical diversity. On the other 
hand, the production of pre-fractionated extract libraries into a format compatible with 
HTS platforms have made screening of extracts easier (Wagenaar 2008). Improvements in 
sensitivity of analytical technologies enable screening and identification of natural 
compounds without laborious isolation steps of compounds from extracts (Dalisay and 
Molinski 2010). 
 
Commercial companies offer large compound libraries for screening in which the 
compounds are designed to fulfil certain criteria, e.g., to be drug-like or contain diverse set 
of compounds spread evenly in the chemical space. The library of 56,320 compounds 
screened in this contribution included commercially available compounds from three 
companies (ChemDiv Inc (San Diego, US), ChemBridge Corporation (San Diego, US) 
and Tripos (St Louis, US). The screening was conducted on random basis and all the 
compounds were assayed in the primary screening phase (IV). In the secondary screening 
phase hits were cherry picked from the plates and serially diluted for the dose response 
determination. The number of compounds and data points was in the range that was 
manageable for the random screening approach in 384-well plate format. 
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The pharmaceutical companies have compound decks that may contain over million 
compounds. The increase in number of compounds per screen does not increase the 
quality of data. On the contrary, focused selection of subset of compounds for a specific 
screen does (Houston et al. 2008). The number of compounds in these subset libraries is in 
the range of 30-60,000 compounds. Selection based on the structural requirement for a 
compound to interact with the specific target class increases the probability in finding 
potent compounds. Highly automated and flexible libraries based on vial storage enable 
creation of subset libraries for each screen separately. When structural information is 
available in the format that computational methods may be utilized for pre-analysis and 
creation of a focused library, the number of compounds needed to be assayed in an in vitro 
set-ups decrease accordingly without decreasing the chance in finding hits. Combinatorial 
chemistry creates lots of closely related compounds which may be utilized to study the 
QSAR of a certain structure in the secondary screening phase (Metzger et al. 2006). 
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6 Summary and Conclusions 
High quality of data created in screening is essential. The assays used should be validated 
and quality parameters should be determined to monitor the assay performance during 
screening. The data created in validated assay set-ups can be utilized for the discrimination 
of an inhibitory effect from the average signal as well as for quantitative analysis such as 
the potency evaluation of an inhibitor. 
 
In this contribution, two AChE inhibitory assays were evaluated as screening tools: TLC 
bioautography and a micro-plate assay based on the Ellman’s reagent. The variants of the 
Ellman’s reagent based assay were studied in more detail to assess how the changes of 
assay conditions affect the potency of inhibitors. The main variants studied were 
measurement time, substrate concentration and the order in which the reaction was 
initiated. The reaction was initiated either with the enzyme (AChE, reaction order 1) or the 
substrate (ATCI, reaction order 2). The quality parameters Z’, S/B and S/N were utilized. 
 
All studied variants of the Ellman’s reagent based assay were validatable when 
measurement time was long enough and variation was low. Z’ value ? 0.5, indicating an 
excellent assay, was achieved at three minutes after initiating the reaction. Also, S/N and 
S/B were above the set limits, ? 10 and ? 4, respectively, for 5 minutes after the initiation 
of  the  reaction.  Some  advantages  were  detected  to  favour  the  reaction  order  2  for  
screening. A part of the substrate hydrolyzes spontaneously. The spontaneous hydrolysis 
increases the background value and the variation between wells when reaction order 1 is 
used because the hydrolysed substrate reacts with the reagent before the enzyme is added. 
Thus, the reaction order 2 had greater a signal window than reaction order 1. In addition, 
with 1.5 mM substrate concentration, the change in absorbance and accordingly the signal 
window is greater than with a substrate concentration of 0.13 mM which can be seen as an 
increase in Z’ values in both variants. 
 
Each library has its pros and cons which makes the selection of the library for screening a 
challenge. When screening extracts for AChE inhibitory effects, separation beforehand 
was  conducted  either  on  TLC  or  HPLC.  The  TLC  separation  was  coupled  with  
bioautography for the detection of AChE and BChE inhibitors in Mentha and fungal 
extracts. HPLC micro-fractionation of the flower extract of Mentha arvensis L. was 
coupled to an off-line AChE assay to track the inhibitory effect to a certain peak in the 
chromatogram. The active compound in Mentha was identified as a known compound, 
linarin, using MS spectroscopy without further isolation of the compound. The active 
compound in one fungal extract, Piptoporus betulinus (Bull.: Fr.) P.Karst extract, was 
isolated directly from the TLC plates and identified as 2,5-dihydroxy-?-oxo-benzeneacetic 
acid using NMR and MS spectroscopy. The fungi were found to be rich sources of 
cholinesterase inhibitors because 115 of the assayed extracts showed AChE inhibitory 
effect and 72 of the extracts showed BChE inhibitory effect. Isolation and identification of 
the active compounds was laborious so only one of the active compounds in the fungal 
extracts was identified. 
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Two pure compound libraries were screened for AChE inhibitory effects: a small 
coumarin library of 29 compounds and a large synthetic compound library of 56,320 
compounds. The hit rate in the coumarin library was substantially higher than in the 
synthetic compound library because this targeted library was created based on a prior 
knowledge on AChE inhibitory effect of the coumarin scaffold. Furthermore, the 
potencies of hits within the synthetic compound library were much higher than the 
potencies of the coumarins. 
 
Both natural and synthetic compound libraries were shown to contain cholinesterase 
inhibitors with various potencies and selectivities, and therefore complement each other as 
sources of compounds for screening. It is acknowledged that natural compounds differ 
structurally from compounds in synthetic compound libraries which further support the 
view of complementation especially if a high diversity of structures is the criterion for 
selection of compounds in a library. The structural difference between natural and 
synthetic compounds was also noted in the analysis of chemical properties of the hits in 
the libraries. The drug discovery process is more demanding and time consuming if 
natural extracts are included in the screening campaign compared to pure compounds due 
to the isolation and identification phases of active compounds. Even so, identification of 
cholinesterase inhibitors in extracts was achieved using LC-MS detection in combination 
with literature search or after isolation of the compound combined with MS and NMR 
analyses. Isolated natural pure compounds, in addition to synthetic compounds, are 
suitable as such for compound libraries for HTS screening. Also, pre-fractionated extracts 
in 96-well plates are compatible with HTS screening platforms which make pre-
fractionation of extracts an alternative way to form natural product libraries. Recent 
improvements in analytical and spectroscopic techniques facilitate following these 
processes. 
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Appendix 1. 
Examples of modification of Ellman’s assay found in the literature and observed half inhibitory concentrations (IC50) for reference compounds. The 
examples were randomly selected from the literature to show wide variety of assay modifications. 
 
AChE source AChE 
concentr./ 
amount 
ATCI 
concentr. 
(mM) 
DTNB 
concentr. 
(mM) 
Reaction initiated  
with enzyme (E) 
or substrate (S) 
Incubation 
time (min) 
Incubation 
temperature 
(°C) 
Measurement 
wavelength 
(nm) 
Measurement  
time 
Reference 
compound(s) 
IC50 (AChE)  
??M) 
Reference 
- 0.028 U/ml 1.5 1.5 E - - 405 2min, 5s intervals galantamine 0.77 Chattipakorn et al. 2007 
eel 0.02 U 0.5 0.3 S 10 37 405 5 min tacrine; 
donepezil 
0.15; 
0.08 
Kwon et al. 2007 
eel 0.022 U/ml 1.5 1.5 E - - 405 13s x 8 galantamine 1.4 Adsersen et al. 2007 
eel 0.028 U/ml 0.15 1.5 E - - 405 2min, 5s intervals galantamine 0.59 Langjae et al. 2007 
eel - - - S 15 25 412 - galantamine - Orhan et al. 2007 
eel - - - S 30 25 412 - physost. 0.04 Atta-ur-Rahman et al. 
2001 
eel 0.022 U/ml 1.5 1.5 E - - 405 after 5 min 
incubation 
galantamine 0.88 Papandreou et al. 2009 
eel - - - According to  
Ellman 1961 
- - - - galantamine 0.55 Tang et al. 2007 
eel 0.056 U/ml 0.3 0.2 S - 25 412 after 5 min physost. 0.073 Vinutha et al. 2007 
eel 0.06 U/ml 0.3 250 S 30 25 405 measured after 
3 min 
galantamine 1.82 Berkov et al. 2008 
eel - - - According to  
Ellman 1961 
- - - - huperzine A; 
huperzine B 
0.8;  
8.0 
Choo et al. 2007 
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AChE source AChE 
concentr./ 
amount 
ATCI 
concentr. 
(mM) 
DTNB 
concentr. 
(mM) 
Reaction initiated  
with enzyme (E) 
or substrate (S) 
Incubation 
time (min) 
Incubation 
temperature 
(°C) 
Measurement 
wavelength 
(nm) 
Measurement  
time 
Reference 
compound(s) 
IC50 (AChE)  
??M) 
Reference 
eel 0.0286 U/ml 1.95 1.92 E - - 405 12 min galantamine 3.18 Lee et al. 2007 
eel 0.01 U/ml 0.5 0.5 S 15 37 412 1 min intervals tacrine 0.1 Pan et al. 2008 
eel - - - S 15 25 412 - physost.;  
tacrine;  
galantamine 
0.041; 
0.021; 
0.45 
Khalid et al. 2004 
eel,  
T.c.,  
bovine erythr.; 
human recomb. 
0.055 U/ml 0.6 0.27 S - 25 412 2 min tacrine 0.074 (eel); 
 0.157 (T.c.);  
0.446 (bovine 
erythr.);  
1.03 (human 
recomb.) 
Sauvaitre et al. 2007 
eel,  
human erythr. 
0.05 U/ml 0.2 0.28 S 10 25 412 1 min tacrine;  
donepezil 
0.039; 0.049 (eel);  
0.096; 0.016 (human 
erythr.) 
Contreras et al. 2001 
human brain 0.02 U 0.5 0.3 S 10 30 405 5 min tacrine 0.167 Munoz-Ruiz et al. 
2005b 
human erythr. - 0.3 0.2 % E - 37 440 reaction stopped 
after 8 min 
tacrine 0.44 Wang et al. 2007 
human erythr. 0.0024 U/ml / 
0.03 U/ml 
0.04 0.024 S 30 4 412 after 20 min,      
37 °C 
galantamine 0.93 Jang et al. 2008 
human erythr. 0.035 U/ml 0.55 0.34 S 20 37 412 5 min physost. 0.014 Rampa et al. 2001 
human erythr 0.035 U/ml 0.55 0.34 S 20 37 412 5 min tacrine 0.25 Recanati et al. 2000 
human erythr. 0.02 U/ml 0.2 0.1 S 20 - 412 5 min physost. 0.019 Villalobos et al. 1994 
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AChE source AChE 
concentr./ 
amount 
ATCI 
concentr. 
(mM) 
DTNB 
concentr. 
(mM) 
Reaction initiated  
with enzyme (E) 
or substrate (S) 
Incubation 
time (min) 
Incubation 
temperature 
(°C) 
Measurement 
wavelength 
(nm) 
Measurement  
time 
Reference 
compound(s) 
IC50 (AChE)  
??M) 
Reference 
human recomb. 0.035U/ml 0.55 0.34 S 20 37 - - donepezil 0.0079 Zhu et al. 2009 
human recomb. 0.02 U/ml 0.55 0.34 S 20 37 - - donepezil 0.02 Rizzo et al. 2010 
human recomb. 0.02 U/ml 0.55 0.34 S 20 37 412 - rivastigmine 0.03 Rizzo et al. 2008 
human recomb.  0.55 0.34 S 20 37 412 5 min donepezil;   
tacrine;  
physost. 
0.023; 
0.424; 
0.013 
Bartolini et al. 2003 
human recomb. 0.1 AU/min 0.55 1.34 S 20-60 37 412 6 min rivastigmine 1.54 Bolognesi et al. 2004 
rat brain;  
eel 
- 54 0.036 S 10 37 412 10 min, 1min 
intervals 
neostigmine 0.04 (rat brain); 
0.053 (eel) 
Girisha et al. 2009 
rat brain - - - According to  
Ellman 1961 
- - - - physost. 0.001 Zhan et al. 2010 
rat brain - - - According to  
Ellman 1961 
- - - - galantamine 0.92 Cardoso et al. 2004 
rat cortex 
homog. 
- 0.3 1.2% E/S 15 37 450 reaction stopped 
after 15 min 
galantamine 1.17 Jia et al. 2009 
rat cortex 
homog. 
- - - E - 37 440 reaction stopped 
after 8 min 
huperzine A; 
huperzine B 
0.072; 0.019 He et al. 2007 
mouse brain 
homog. 
- 0.5  E 2 or 60 25 412 - physost. 0.00069 with  
60 min preincub.; 
0.34 without 
preincub. 
Sugimoto et al. 1990 
T.c. 0.028 U/ml 0.15 1.5 E - - 405 2min, 5s intervals galantamine 0.6 Sangnoi et al. 2008 
T.c. Torpedo californica; eel Electrophorus electricus, physost. physostigmine 
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